<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85647</article-id><article-id pub-id-type="doi">10.7554/eLife.85647</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>TLR7 activation at epithelial barriers promotes emergency myelopoiesis and lung antiviral immunity</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-157551"><name><surname>Jackson</surname><given-names>William D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-302894"><name><surname>Giacomassi</surname><given-names>Chiara</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0462-0381</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157548"><name><surname>Ward</surname><given-names>Sophie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302895"><name><surname>Owen</surname><given-names>Amber</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-135612"><name><surname>Luis</surname><given-names>Tiago C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6305-1257</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-302896"><name><surname>Spear</surname><given-names>Sarah</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4306-3752</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35869"><name><surname>Woollard</surname><given-names>Kevin J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9839-5463</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-16836"><name><surname>Johansson</surname><given-names>Cecilia</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157120"><name><surname>Strid</surname><given-names>Jessica</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3690-2201</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-215596"><name><surname>Botto</surname><given-names>Marina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1458-3791</contrib-id><email>m.botto@imperial.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>National Heart and Lung Institute, Imperial College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>Division of Cancer, Department of Surgery and Cancer, Imperial College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Noble</surname><given-names>Paul W</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pammg90</institution-id><institution>Cedars-Sinai Medical Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Noble</surname><given-names>Paul W</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pammg90</institution-id><institution>Cedars-Sinai Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>William Harvey Research Institute, Queen Mary University of London, London, United Kingdom</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>11</day><month>08</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e85647</elocation-id><history><date date-type="received" iso-8601-date="2022-12-17"><day>17</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-08-10"><day>10</day><month>08</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2023-02-07"><day>07</day><month>02</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.02.06.527328"/></event></pub-history><permissions><copyright-statement>© 2023, Jackson, Giacomassi et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Jackson, Giacomassi et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-85647-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-85647-figures-v2.pdf"/><abstract><p>Monocytes are heterogeneous innate effector leukocytes generated in the bone marrow and released into circulation in a CCR2-dependent manner. During infection or inflammation, myelopoiesis is modulated to rapidly meet the demand for more effector cells. Danger signals from peripheral tissues can influence this process. Herein we demonstrate that repetitive TLR7 stimulation via the epithelial barriers drove a potent emergency bone marrow monocyte response in mice. This process was unique to TLR7 activation and occurred independently of the canonical CCR2 and CX3CR1 axes or prototypical cytokines. The monocytes egressing the bone marrow had an immature Ly6C-high profile and differentiated into vascular Ly6C-low monocytes and tissue macrophages in multiple organs. They displayed a blunted cytokine response to further TLR7 stimulation and reduced lung viral load after RSV and influenza virus infection. These data provide insights into the emergency myelopoiesis likely to occur in response to the encounter of single-stranded RNA viruses at barrier sites.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>monocytes</kwd><kwd>TLR</kwd><kwd>virus</kwd><kwd>skin</kwd><kwd>haematopoiesis</kwd><kwd>macrophages</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>108008/Z/15/Z</award-id><principal-award-recipient><name><surname>Botto</surname><given-names>Marina</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>102126/B/13/Z</award-id><principal-award-recipient><name><surname>Johansson</surname><given-names>Cecilia</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004440</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>Institutional Strategic Support Fund</award-id><principal-award-recipient><name><surname>Giacomassi</surname><given-names>Chiara</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>Sir Henry Dale Fellowship - Wellcome Trust/Royal Society of Medicine 210424/Z/18/Z</award-id><principal-award-recipient><name><surname>Luis</surname><given-names>Tiago C</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000402</institution-id><institution>Kay Kendall Leukaemia Fund</institution></institution-wrap></funding-source><award-id>KKL1379</award-id><principal-award-recipient><name><surname>Luis</surname><given-names>Tiago C</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000828</institution-id><institution>Royal Society of Medicine</institution></institution-wrap></funding-source><award-id>Sir Henry Dale Fellowship - Wellcome Trust/Royal Society of Medicine 210424/Z/18/Z</award-id><principal-award-recipient><name><surname>Luis</surname><given-names>Tiago C</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A novel pathway of emergency myelopoiesis is induced by repetitive virus stimulation at peripheral barrier sites which bypasses the requirement of conventional pathways and expands myeloid infiltration in tissues.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Monocytes are circulating, short-lived mononuclear phagocytes critical for host defence against infection. In mice, there are at least two subpopulations of blood monocytes defined by their expression of lymphocyte antigen 6C (Ly6C) (<xref ref-type="bibr" rid="bib25">Geissmann et al., 2003</xref>). Ly6C-high monocytes are ‘classical’ inflammatory monocytes, which express high levels of CCR2, low levels of CX3CR1, and respond to canonical bacterial cues such as lipopolysaccharide (LPS). Ly6C-low monocytes are defined as ‘non-classical’, expressing low levels of CCR2 and high levels of CX3CR1 (<xref ref-type="bibr" rid="bib25">Geissmann et al., 2003</xref>). These non-classical monocytes patrol the vascular lumen during times of homeostasis, surveying its integrity and orchestrating the disposal of damaged endothelial cells and subsequent inflammatory response (<xref ref-type="bibr" rid="bib5">Auffray et al., 2007</xref>; <xref ref-type="bibr" rid="bib12">Carlin et al., 2013</xref>; <xref ref-type="bibr" rid="bib71">Turner-Stokes et al., 2020</xref>). This patrolling behaviour is independent of the normal leukocyte adhesion cascade and requires firm adhesion via the β2-integrin LFA1 (<xref ref-type="bibr" rid="bib12">Carlin et al., 2013</xref>). Non-classical monocytes can respond directly to viral cues via toll-like receptor 7 (TLR7), yet respond poorly to LPS (<xref ref-type="bibr" rid="bib17">Cros et al., 2010</xref>). The existence of a heterogeneous, MHC-II-high-intermediate population has also been suggested (<xref ref-type="bibr" rid="bib47">Menezes et al., 2016</xref>; <xref ref-type="bibr" rid="bib48">Mildner et al., 2017</xref>), but in mice the functional distinction of intermediate monocytes remains unclear. Despite widespread usage, this classification system may oversimplify monocyte heterogeneity as mass cytometry has identified up to eight subpopulations of monocytes in healthy human blood (<xref ref-type="bibr" rid="bib31">Hamers et al., 2019</xref>) and novel subpopulations can emerge during inflammation and fibrosis (<xref ref-type="bibr" rid="bib58">Satoh et al., 2017</xref>), such as Sca-1-positive ‘emergency monocytes’ during parasite infection (<xref ref-type="bibr" rid="bib1">Abidin et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Askenase et al., 2015</xref>).</p><p>In steady-state conditions, monocytes are produced in the bone marrow (BM) where they are derived from commitment of haematopoietic stem and progenitor cells (HSPCs) along a defined pathway that culminates in terminally differentiated mature monocytes. Although still debated, the most widely accepted of these pathways is the sequential commitment of HSPCs to the common myeloid progenitor (CMP), the monocyte-dendritic cell progenitor (MDP), and the common monocyte progenitor (cMoP), before finally generating BM monocytes (<xref ref-type="bibr" rid="bib77">Wolf et al., 2019</xref>) in a process that is dependent on the colony-stimulating factor 1 (CSF1) and the transcription factor PU.1 (<xref ref-type="bibr" rid="bib22">DeKoter et al., 1998</xref>). In addition, the work of Goodridge and colleagues suggests a functionally distinct monocyte population that can be derived from the granulocyte-monocyte progenitor (GMP), bypassing the MDP and the cMoP (<xref ref-type="bibr" rid="bib79">Yáñez et al., 2017</xref>). The first monocyte population to be produced in the BM are the Ly6C-high monocytes, which during homeostasis are obligate precursors for Ly6C-low monocytes in a CEBP-β dependent process (<xref ref-type="bibr" rid="bib48">Mildner et al., 2017</xref>). This is consistent with previous findings using transgenic fate mapping mice (<xref ref-type="bibr" rid="bib80">Yona et al., 2013</xref>), direct adoptive transfer of Ly6C+ monocytes (<xref ref-type="bibr" rid="bib73">Varol et al., 2007</xref>; <xref ref-type="bibr" rid="bib80">Yona et al., 2013</xref>), and re-population kinetic studies following depletion regimes (<xref ref-type="bibr" rid="bib67">Sunderkötter et al., 2004</xref>). The same process has also been suggested to occur in humans (<xref ref-type="bibr" rid="bib52">Patel et al., 2017</xref>). Ly6C-high monocytes have a circulating half-life of &lt;1 d in both mice and humans before converting through an intermediate stage into Ly6C-low monocytes, which can remain in the blood for between ~2 and 7 d (<xref ref-type="bibr" rid="bib52">Patel et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Yona et al., 2013</xref>). The egression of Ly6C-high monocytes from the BM is largely dependent on the C-C chemokine receptor type 2 (CCR2) (<xref ref-type="bibr" rid="bib70">Tsou et al., 2007</xref>). Similarly, Ly6C-high monocyte extravasation into tissues is mediated by CCR2 in response to local production of the C–C motif chemokine ligand 2 (CCL2) or 7 (CCL7) (<xref ref-type="bibr" rid="bib63">Shi and Pamer, 2011</xref>). However, the dynamics of monocyte subpopulation production and BM egression during inflammation and/or infection remain poorly understood.</p><p>During infection or tissue injury, monocytes are crucial for controlling the invading pathogen (<xref ref-type="bibr" rid="bib30">Haist et al., 2017</xref>; <xref ref-type="bibr" rid="bib63">Shi and Pamer, 2011</xref>) or for regulating the tissue repair process (<xref ref-type="bibr" rid="bib78">Wynn and Vannella, 2016</xref>). For example, the recruitment of Ly6C-high inflammatory monocytes in the lungs in response to respiratory pathogens like respiratory syncytial virus (RSV) is essential to control viral load and lessen disease severity (<xref ref-type="bibr" rid="bib27">Goritzka et al., 2015</xref>). As such, the process of myelopoiesis is differentially regulated during infection or inflammation to rapidly meet demand for ‘emergency’ effector monocytes or neutrophils. An acute requirement for additional monocytes can either be met by the spleen via a reservoir of mature splenic monocytes and accompanying extramedullary haematopoiesis (<xref ref-type="bibr" rid="bib68">Swirski et al., 2009</xref>) or by conventional BM haematopoiesis (<xref ref-type="bibr" rid="bib77">Wolf et al., 2019</xref>). A key component of the ‘emergency’ process is sensing and communicating the danger signals to the haemopoietic progenitor pool in either the BM or the spleen. This occurs primarily through activation of pattern recognition receptors (PRRs), most notably the TLR family, whose expression has been confirmed on HSPCs in both human and mouse (<xref ref-type="bibr" rid="bib50">Nagai et al., 2006</xref>; <xref ref-type="bibr" rid="bib65">Sioud et al., 2006</xref>). The sensing of pathogens by the haematopoietic system can either occur directly or as a secondary effect of inflammatory mediators produced at the barrier sites such as the skin or the gut (<xref ref-type="bibr" rid="bib4">Askenase et al., 2015</xref>; <xref ref-type="bibr" rid="bib8">Baldridge et al., 2010</xref>; <xref ref-type="bibr" rid="bib55">Pietras et al., 2016</xref>) or by BM stromal cells (<xref ref-type="bibr" rid="bib63">Shi and Pamer, 2011</xref>). The nature of the distal signals from barrier sites to BM and the features of the ‘emergency’ processes triggered under different settings remain largely unknown.</p><p>The skin is the largest barrier site in the body and is targeted as an entry point by a variety of pathogens, perhaps most notably the diverse group of arboviruses spread by mosquitoes. These infect hundreds of millions of people annually and include serious threats to human health such as dengue virus and Zika virus, both of which are single-stranded RNA viruses sensed by TLR7 (<xref ref-type="bibr" rid="bib51">Paixão et al., 2018</xref>). Recently, it has been shown that the skin immune response via TLR7 expressed in dermal dendritic cells can locally protect against a second viral infection at the inoculation site (<xref ref-type="bibr" rid="bib10">Bryden et al., 2020</xref>). However, it is unclear what effect TLR7 activation at the epithelial barrier has on the haematopoietic system and the subsequent innate immune response in other organs. Here we used R848, a TLR7/8 agonist, and demonstrate that only persistent TLR7 stimulation at an epithelial barrier such as the skin or gut was able to drive a unique CCR2-independent BM emergency monocyte response. This process was characterised by the release of immature Ly6C-high pre-monocytes into the periphery and their differentiation to both Ly6C-low monocytes in the blood and to tissue macrophages in multiple organs. The emergency monocytes released by the BM under these conditions displayed an impaired response to TLR7 restimulation and promoted lung viral control, which dampened disease severity after RSV and influenza virus infection.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Persistent TLR7 stimulation at epithelial barrier sites drives systemic monocytosis</title><p>To investigate how the haematopoietic response to a single-stranded RNA virus could be influenced by the point of entry, we administered a TLR7 agonist, R848, to BALB/c mice topically or intraperitoneally (IP) (100 µg, three times a week for 4 wk, equivalent to 12 treatments) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>) and observed a marked monocytosis only in the topical R848 group (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). While blood monocyte counts (CD11b+CD115+) in vehicle and IP-treated mice remained largely unchanged (mean of 850.8 ± 159/µl), mice that received topical R848 had a mean monocyte count of 25,154 ± 2956/µl, an approximately 30-fold expansion (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The monocytosis was accompanied by a ratio switch in the Ly6C-high and Ly6C-low monocyte subpopulations, with the Ly6C-low population accounting for &gt;90% of total monocytes after topical R848 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We also found a pronounced splenomegaly in the topically treated mice which was not present in the mice receiving R848 IP (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). To investigate the kinetics of the monocytosis, mice were treated with topical R848 four times and blood samples were taken 24 hr after each treatment. After one treatment, we observed a marked drop in monocyte (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) and lymphocyte (both CD3+ T cell and B220+ B cell) counts (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). While the lymphocyte counts slowly returned within the normal range by four treatments (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), both monocyte subpopulations expanded quickly after two treatments (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). On subsequent R848 applications, the Ly6C-low monocyte population continued to expand, whilst the level of Ly6C-high monocytes remained stable (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), ultimately leading to a ratio switch (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) as in <xref ref-type="fig" rid="fig1">Figure 1A</xref>. Throughout the time course, no change was seen in blood neutrophil counts (CD11b+Ly6G+Ly6C-low), indicating that topical R848 does not trigger a pan-myeloid response (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). To confirm that the monocyte response was not due to the systemic diffusion of the compound, we administered R848 intravenously (IV) and compared it to topical application. While both routes of administration caused lymphopenia, only the topical route was able to promote monocytosis and a ratio switch toward Ly6C-low monocytes (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). We then reasoned that perhaps the monocyte response triggered by TLR7 activation was specific to epithelial barrier sites. To test if this was a unique response to topical challenge, R848 was dissolved in the drinking water at a concentration that was calculated to be equivalent to the dose applied topically (<xref ref-type="bibr" rid="bib6">Bachmanov et al., 2002</xref>). Oral R848 induced a monocytosis with a proportional switch toward Ly6C-low monocytes that was comparable to that seen after topical treatment (<xref ref-type="fig" rid="fig1">Figure 1F</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Repetitive R848 administration at barrier sites drives a profound monocytosis.</title><p>(<bold>A</bold>) BALB/c mice (n = 3 per group) received 100 µg of R848 topically or intraperitoneally (IP), 3× per week for 4 wk. Control BALB/c mice were given topical acetone or 200 µl of PBS IP. Left panel shows the number of total monocytes (CD11b+CD115+), the right panel the ratio between Ly6C-high and Ly6C-low monocytes. (<bold>B</bold>) BALB/c mice (n = 3 per group) received four treatments of topical R848 (100 µg). Numbers of Ly6C-high (grey bars) and Ly6C-low (black bars) monocyte 24 hr after each treatment. (<bold>C</bold>) Representative plots of total monocytes (left panel) and of subpopulations (right panel) in mice treated topically with acetone or R848 four times. (<bold>D</bold>) Mice treated as in (<bold>B</bold>). Neutrophil counts 24 hr after each treatment. (<bold>E</bold>) BALB/c mice (n = 4 per group) received six treatments with 100 µg topical (red line) or IV R848 (black line). Blood counts are shown for total monocytes, Ly6C-high monocytes, Ly6C-low monocytes, monocyte subpopulation ratio and lymphocytes at 24 hr after the indicated treatment. (<bold>F</bold>) C57BL/6 mice were given drinking water containing 8.3 µg/ml R848 (blue line, n = 10) or vehicle control (black line, n = 12) for 11 d. Blood counts are shown for total monocytes, Ly6C-high monocytes, Ly6C-low monocytes, monocyte subpopulation ratio and lymphocytes at the indicated time point. Data representative of at least two independent experiments (except <bold>A</bold>). One-way ANOVA with Bonferroni’s multiple-comparison test (<bold>A</bold>); two-way ANOVA with Tukey’s multiple comparison for analysis of time-course experiments (<bold>B, D–F</bold>). Data are the mean ± SEM; only significant p-values are indicated; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>FACS raw data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85647-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85647-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>The effects of TLR7 stimulation depend on dose and route of administration.</title><p>(<bold>A</bold>) Graphical illustration of R848 treatment regimen. (<bold>B</bold>) BALB/c mice (n = 3 per group) received 100 μg of R848 topically or intraperitoneally (IP), 3× per week for 4 wk. Control mice given topical acetone or 200 μl of PBS IP. Splenomegaly quantified as spleen: body weight ratio, with representative example shown. (<bold>C</bold>) BALB/c mice (n = 3 per group) received four treatments with 100 μg topical R848 (black squares) or acetone (open squares). Blood counts are shown (left to right) for total leukocytes, B-cells, CD4+ T cells and CD8+ T cells 24 hr after each treatment. (<bold>D, E</bold>) Blood counts for total monocytes, Ly6C-high monocytes, Ly6C-low monocytes and B cells 24 hr after each treatment. (<bold>D</bold>) C57BL/6 mice (n = 4 per group) received 6× IP treatments with 1 μg (open circles), 10 μg (black squares), or 100 μg R848 (black triangles) or PBS vehicle (red triangles). Statistics versus vehicle group. (<bold>E</bold>) C57BL/6 mice (n = 4 per group) received 4× topical treatments with 1 μg (open circles), 10 μg (blue squares), or 100 μg R848 (red triangles). Statistics show pre-bleed vs. four treatments. (<bold>F</bold>) C57BL/6 mice were either naive (red circles, n = 3) or received six daily topical treatments with imiquimod (IMQ, blue triangles, n = 5) or R848 (black squares, n = 5). Blood counts 24 hr after the indicated treatments. Statistics versus naive group. Data representative of two experiments (except <bold>B</bold> and <bold>E</bold>). One-way ANOVA with Bonferroni’s multiple-comparison test for a single time point (<bold>B</bold>); two-way ANOVA with Tukey’s multiple-comparison test for analysis of time-course experiments (<bold>C–F</bold>). Data are the mean ± SEM; only significant p-values are indicated; ***p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85647-fig1-figsupp1-v2.tif"/></fig></fig-group><p>As the response to other TLR stimuli such as LPS is dose-dependent and repeated administrations can either result in sensitisation or tolerance, which is considered a form of ‘innate immune memory’ (<xref ref-type="bibr" rid="bib9">Biswas and Lopez-Collazo, 2009</xref>), we performed a dose–response experiment with R848 given IP. None of the doses tested caused a significant increase in blood monocyte counts when compared to vehicle (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). In addition, the monocytosis following topical R848 was clearly dose dependent, with 100 µg inducing a strong response, 1 µg causing no change, and the 10 µg group displaying an intermediate phenotype (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Consistent with the dose–response data, application of imiquimod (IMQ), which is an ~100-fold less potent agonist, did not elevate peripheral monocyte counts even after six daily treatments (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Together these data demonstrate that a persistent and potent TLR7 stimulation at an epithelial barrier can trigger a distinctive innate immune response characterised by a profound monocytosis.</p></sec><sec id="s2-2"><title>Skin-induced monocytosis requires TLR7 activation</title><p>We next sought to investigate whether the monocyte response via an epithelial barrier could also be promoted by other TLR stimuli. We therefore treated mice topically with LPS or poly I:C (TLR4 and TLR3/RIG-I agonists, respectively), alongside an R848 control group. For this experiment, we utilised a modified water-soluble version of R848 to allow all agonists to be dissolved in the same vehicle. As previously, topical R848 triggered an immediate leukopenia followed by the characteristic monocytosis dominated by Ly6C-low monocytes, whereas LPS and poly I:C had no substantial effects on blood cell counts (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Similarly, topical application of a TLR9 agonist, CpG oligodeoxynucleotides (ODNs), neither changed monocyte counts nor caused lymphopenia (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Moreover, topical application of the potent pro-inflammatory stimulus 12-O-tetradecanoylphorbol-13-acetate (TPA) did not affect monocyte counts after four treatments (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). In view of the marked difference between the effects induced by R848 and the other TLR agonists, we next used TLR7-deficient (<italic>Tlr7<sup>-/-</sup></italic>) mice to exclude activation of TLR8 or inflammasome, or any off-target effects of the R848 compound. Total monocytes and Ly6C-low monocytes were significantly elevated in the wild-type (WT) animals, while <italic>Tlr7<sup>-/-</sup></italic> mice did not show a response to R848 confirming the specificity of the pathway involved (<xref ref-type="fig" rid="fig2">Figure 2D</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>R848-induced monocytosis is specific to TLR7 activation.</title><p>Blood counts are shown for total monocytes, Ly6C-high monocytes, Ly6C-low monocytes, monocyte subpopulation ratio, and lymphocytes 24 hr after the indicated treatment. (<bold>A</bold>) BALB/c mice (n = 4 per group) received eight treatments with topical R848 (100 µg, black line), LPS (100 µg, blue line), or Poly l:C (100 µg, red line). (<bold>B</bold>) C57BL/6 mice received six treatments with topical R848 (100 µg, n = 5, black line) or CpG (100 µg, n = 3, red line). (<bold>C</bold>) BALB/c mice (n = 4 per group) received four topical treatments with 2.5 nmol TPA. (<bold>D</bold>) C57BL/6 mice (n = 5, black triangles) or <italic>Tlr7</italic><sup>-/-</sup> mice (n = 5, red circles) received four treatments with topical R848. Data representative of two independent experiments (except <bold>A</bold> and <bold>C</bold>). Two-way ANOVA with Tukey’s multiple-comparison for time-course experiments (<bold>A, B</bold>); unpaired <italic>t</italic>-test (<bold>C, D</bold>). Data are the mean ± SEM; only significant p-values are indicated; *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>FACS raw data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85647-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85647-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>IFNs and cytokines are not involved in the R848-induced monocytosis.</title><p>(<bold>A</bold>) C57BL/6 (black triangles) or <italic>Ifng<sup>-/-</sup></italic> mice (red squares) were either left untreated (n = 4 WT, n = 2 <italic>Ifng<sup>-/-</sup></italic>) or given 4× topical treatments with R848 (n = 3 per group). Blood counts for total monocytes, Ly6C-high monocytes, Ly6C-low monocytes, and the monocyte subpopulation ratio at baseline and at 24 hr after the indicated treatment. Data representative of two independent experiments. (<bold>B</bold>) C57BL/6 (n = 4, black squares) or <italic>Ifnar1<sup>-/-</sup></italic> (n = 5, blue triangles) mice received eight topical treatments with R848. Blood counts for total monocytes, Ly6C-high monocytes, Ly6C-low monocytes, and the monocyte subpopulation ratio at baseline and 24 hr after the indicated treatments. (<bold>C</bold>) BALB/c mice were treated daily intraperitoneally (IP) with etanercept (anti-TNFα) (n = 6, blue squares) or PBS (n = 6, open circles) and then received 4× topical R848 treatments. Blood counts for total monocytes, Ly6C-high monocytes, Ly6C-low monocytes, and the monocyte subpopulation ratio at baseline and at 24 hr after the indicated treatment. (<bold>D</bold>) BALB/c mice received the following combinations: topical R848 and anakinra daily IP (n = 4, open circles), topical R848 and daily PBS IP (n = 4, black triangles), and topical acetone and anakinra daily IP (n = 4, red squares). Blood counts for total monocytes, Ly6C-high monocytes, Ly6C-low monocytes, and the monocyte subpopulation ratio at baseline and at 24 hr after the fourth treatment of R848. (<bold>E</bold>) BALB/c mice were treated IP with PBS (n = 6, open circles) or anti-IL6R (n = 6, blue squares) or the isotype control (n = 6, red triangle) every 3 d and received 4× topical R848 applications. Blood counts for total monocytes, Ly6C-high monocytes, Ly6C-low monocytes, and the monocyte subpopulation ratio at baseline and at 24 hr after the fourth treatment with R848. Time-course experiments analysed using two-way ANOVA with Tukey’s multiple-comparison test to compare between time points (<bold>A–C</bold>); one-way ANOVA with Bonferroni’s multiple-comparison test for comparing &gt;2 groups at a single time point calculated (<bold>D, E</bold>). Data are the mean ± SEM; only significant p-values are indicated; *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85647-fig2-figsupp1-v2.tif"/></fig></fig-group><p>Various cytokines have previously been implicated in the regulation of myeloid cell production during inflammation, most notably the interferon (IFN) family and IL1β (<xref ref-type="bibr" rid="bib4">Askenase et al., 2015</xref>; <xref ref-type="bibr" rid="bib11">Buechler et al., 2013</xref>; <xref ref-type="bibr" rid="bib49">Mitroulis et al., 2018</xref>). We found no obvious differences in monocyte counts after topical R848 treatments in either IFN-y- or IFNAR1-deficient mice compared to the WT animals (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), discounting a role for type I and type II IFNs. We then utilised the IL-1 receptor antagonist anakinra, which has been reported to cross-react with the mouse protein (<xref ref-type="bibr" rid="bib36">Iannitti et al., 2016</xref>), and observed no differences in the induction of monocytosis or the monocyte subpopulation ratio (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>), making the involvement of IL-1 unlikely. In addition, blocking IL-6 and TNF-α signalling did not prevent the onset of monocytosis (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). These data collectively suggest that only activation of the TLR7 pathway at the skin barrier can drive the changes in the myeloid compartment that occur independently from inflammasome activation or some of the well-established cytokine-mediated pathways.</p></sec><sec id="s2-3"><title>Myeloid cells orchestrate the R848-induced monocytosis</title><p>We next attempted to determine which cells initiate the monocyte response. We first generated BM chimeras using <italic>Tlr7<sup>-/-</sup></italic> mice (<xref ref-type="bibr" rid="bib33">Hemmi et al., 2002</xref>) to distinguish between stromal and haematopoietic cells. BM reconstituted mice were treated with topical R848 and monocyte response assessed. After four treatments, there was a marked increase in the proportion of total monocytes and Ly6C-low monocytes in the mice that received WT BM, but not in mice that received <italic>Tlr7<sup>-/-</sup></italic> BM, regardless of the host genotype (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), indicating that cells of haematopoietic origin and not irradiation-resistant skin-resident cells like stromal or epithelial cells were responsible for the myeloid response to R848.</p><p>To identify the BM-derived cells responding to the TLR7 activation, we first utilised <italic>Rag2<sup>-/-</sup></italic> mice, which lack both T- and B cells (<xref ref-type="bibr" rid="bib64">Shinkai et al., 1992</xref>). After four topical treatments with R848, both WT and <italic>Rag2<sup>-/-</sup></italic> animals developed a monocytosis dominated by Ly6C-low cells (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), indicating that lymphocytes are dispensable. We then crossed <italic>Tlr7</italic>-floxed mice (<xref ref-type="bibr" rid="bib66">Solmaz et al., 2019</xref>) with <italic>Lyz2<sup>Cre/Cre</sup></italic> animals, which express the Cre recombinase in monocytes, neutrophils, and some macrophage populations (<xref ref-type="bibr" rid="bib2">Abram et al., 2014</xref>). While after R848 treatment both WT and <italic>Lyz2<sup>Cre/+</sup> × Tlr7<sup>fl</sup></italic> mice developed monocytosis, this expansion was reduced by &gt;50% in the mice lacking TLR7 in <italic>Lyz2</italic>-expressing cells (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), demonstrating that Lyz2-expressing cells were at least partially responsible for the skin response to TLR7 activation. As mast cells, eosinophils, and basophils are not reported to express <italic>Lyz2</italic> (<xref ref-type="bibr" rid="bib2">Abram et al., 2014</xref>), we investigated these cells individually. <italic>ΔdblGATA</italic> mice, lacking eosinophils, and <italic>Cpa3<sup>Cre/</sup></italic><sup>+</sup> mice, lacking both mast cells and basophils, did not show any obvious defect in their response to R848 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). In addition, neutrophils depletion using an anti-Ly6G depletion antibody (<xref ref-type="bibr" rid="bib18">Daley et al., 2008</xref>) failed to abolish the monocytosis. On the contrary, it increased the R848-induced monocytosis (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>) consistent with the observation that (<xref ref-type="bibr" rid="bib16">Cortez-Retamozo et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Swirski et al., 2009</xref>) neutrophil depletion can trigger a mild degree of monocytosis (<xref ref-type="bibr" rid="bib53">Patel et al., 2019</xref>). In light of these observations, we concluded that a BM-derived myeloid population was contributing to promote the systemic response following TLR7 activation.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>R848-induced monocytosis is driven by TLR7 activation of myeloid cells.</title><p>(<bold>A, B</bold>) Blood counts for total monocytes, Ly6C-high monocytes, Ly6C-low monocytes, monocyte subpopulation ratio, and lymphocytes at baseline and 24 hr after the indicated treatment. (<bold>A</bold>) C57BL/6 mice (n = 5, black triangles) and <italic>Rag2</italic><sup>-/-</sup> mice (n = 6, blue circles) received four topical treatments with R848. (<bold>B</bold>) C57BL/6 mice (n = 6, black rhombi) and <italic>Tlr7</italic><sup><italic>fl</italic></sup> × <italic>Lyz2</italic><sup><italic>Cre</italic>/+</sup> mice (n = 5, red triangles) received six topical treatments with R848. (<bold>C</bold>) C57BL/6 mice (n = 3 per group) were treated once or twice with topical R848 or acetone. Treated ear skin was harvested at 24 hr post-treatment and anal- ysed by flow cytometry. Proportion of monocytes (CD11b+Ly6C+Ly6G-low) and neutrophils (CD11b+Ly6G-high- Ly6C-low) among total live cells (left panels). Representative flow cytometry plots gated on CD11b+ cells (right panels). Data represent a single experiment (<bold>A, C</bold>) or two experiments (<bold>B</bold>). Two-way ANOVA, with Tukey’s multiple-comparison for time-course experiments (<bold>A, B</bold>); unpaired <italic>t</italic>-test (<bold>C</bold>). Data are the mean ± SEM; only significant p-values are indicated; *p&lt;0.05; **p&lt;0.01.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>FACS raw data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85647-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85647-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>The role of myeloid cell populations in R848-driven monocytosis.</title><p>(<bold>A</bold>) Lethally irradiated WT or <italic>Tlr7<sup>-/-</sup></italic> host mice were reconstituted with bone marrow (BM) from WT or <italic>Tlr7<sup>-/-</sup></italic> donor mice as follows: WT BM into WT host (n = 5, open circles), WT BM into <italic>Tlr7<sup>-/-</sup></italic> host (n = 5, red triangles), <italic>Tlr7<sup>-/-</sup></italic> BM into WT host (n = 5, crosses), and <italic>Tlr7<sup>-/-</sup></italic> BM into <italic>Tlr7<sup>-/-</sup></italic> host (n = 5, red squares). Each group received 4× topical treatments with R848. Total blood monocytes, Ly6C-high monocytes, and Ly6C-low monocytes are shown as a proportion of CD45+ cells, at baseline and 24 hr after the indicated treatments. (<bold>B–D</bold>) Blood counts for total monocytes, Ly6C-high monocytes, Ly6C-low monocytes, and the monocyte subpopulation ratio at baseline and 24 hr after the indicated R848 treatments. (<bold>B</bold>) BALB/c (n = 4, black triangles) or <italic>ΔdblGATA</italic> (n = 6, red squares) mice received six topical treatments with R848. (<bold>C</bold>) BALB/c mice were either treated with topical R848 (n = 4, black squares) alongside a group of <italic>Cpa3-Cre<sup>-/+</sup></italic> mice (n = 4, blue triangles). (<bold>D</bold>) BALB/c mice were treated with combinations of topical R848 and intraperitoneally (IP) anti-Ly6G or anti-FITC isotype control, with the antibody injected 4 hr prior to the first R848 treatment. Treatments were in the following groups: isotype control and R848 (n = 5, red triangles), anti-Ly6G and R848 (n = 4, blue squares), and anti-Ly6G alone (n = 5, black circles). Statistics compare anti-Ly6G+R848 to anti-FITC+R848. Time-course experiments analysed using two-way ANOVA with Tukey’s multiple-comparisons test to compare between groups at a given time point (<bold>A–D</bold>); one-way ANOVA with Bonferroni’s multiple-comparison test for comparing &gt;2 groups at a single time point; unpaired <italic>t</italic>-test for comparing two groups at a single time point. Data are the mean ± SEM; only significant p-values are indicated; * p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85647-fig3-figsupp1-v2.tif"/></fig></fig-group><p>We next explored whether local tissue-infiltrating myeloid cells were involved in the systemic response. We applied R848 twice and observed infiltration of monocytes in the skin after the first treatment (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), suggesting that these BM-derived myeloid cells were not only involved in triggering the initial response to TLR7 stimulation, but also acted in a positive feedback manner and played a key role in maintaining the systemic myelopoiesis.</p></sec><sec id="s2-4"><title>The emergency monocyte response triggered by cutaneous R848 originates in the BM</title><p>While haematopoiesis of myeloid cells during homeostasis occurs predominantly in the BM, under pathological conditions this can be superseded by extramedullary haematopoiesis in the spleen (<xref ref-type="bibr" rid="bib16">Cortez-Retamozo et al., 2012</xref>; <xref ref-type="bibr" rid="bib68">Swirski et al., 2009</xref>). To understand the source of the monocyte response triggered by cutaneous TLR7 activation, we performed splenectomy or sham surgery and applied topical R848 treatment after the mice had fully recovered from the surgery. Monocytosis and a ratio switch towards Ly6C-low monocytes occurred in the R848-treated mice with or without spleen and were markedly different from the untreated splenectomised mice (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), indicating that the stimulation of TLR7 at the skin barrier was driving a haematopoietic response mainly in the BM. Of note, the R848-treated splenectomised mice showed a slightly enhanced phenotype, suggesting that the spleen may retain some of the circulating monocytes. To confirm the BM origin of the R848-induced monocytosis, we conducted in vivo fate-tracing experiments using HSC-SCL-CreER<sup>T</sup>;R26EYFP mice (<xref ref-type="bibr" rid="bib28">Göthert et al., 2005</xref>). Under our experimental conditions, tamoxifen administration induced recombination in ~45% of the BM HSCs (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>) with no recombination in the peripheral blood. Consistent with previous experiments, the tamoxifen-treated HSC-SCL-CreER<sup>T</sup>;R26EYFP mice responded to the topical R848 with a marked increase in the total monocyte count and a ratio switch towards Ly6C-low monocytes (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), indicating that neither the genetic modification nor the tamoxifen had altered the BM response. Importantly, the same pattern was observed among the EYFP-positive monocytes that were predominantly Ly6c-low monocytes (<xref ref-type="fig" rid="fig4">Figure 4C</xref>), confirming that the R848-induced monocytes originates mainly from the BM.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>R848-induced monocytes are derived from the bone marrow (BM) and have features of emergency myelopoiesis.</title><p>(<bold>A</bold>) BALB/c mice underwent splenectomy or sham surgery and were left to recover for 7 wk. Among the splenectomised mice, a group was treated 6× with topical R848 (n = 4, blue line) and the remaining mice with acetone (n = 3, solid black line). The sham surgery group was treated with R848 (n = 4, red line). Blood counts are shown for total monocytes, Ly6C-high monocytes, Ly6C-low monocytes, and the monocyte subpopulation ratio at baseline and 24 hr after the last treatments. (<bold>B, C</bold>) HSC-SCL-Cre-ERT;R26R-EYFP mice (n = 4 per group) received tamoxifen (4 mg/100 µl) by oral gavage for five consecutive days. Three days later, the left ears were treated topically 4× with R848 (blue squares) or left untreated (open circles). Shown are the total blood monocyte counts and the monocyte subpopulation ratio (<bold>B</bold>); the total blood EYFP+ monocyte counts and the subpopulation ratio among the EYFP-expressing monocytes at baseline and 24 hr after the last treatment (<bold>C</bold>). (<bold>D</bold>) Diagram illustrating BM myeloid progenitor differentiation: haematopoietic stem and progenitor cells (HSPC); common myeloid progenitor (CMP); monocyte-dendritic precursor (MDP); granulocyte-monocyte progenitor (GMP); common monocyte progenitor (cMoP); common dendritic progenitor (CDP); monocyte-committed progenitor (MP); granulocyte-committed progenitor (GP). (<bold>E–G</bold>) C57BL/6 mice were injected with 2 mg BRDU intraperitoneally (IP), either naïve (n = 3, white bars) or after two topical R848 treatments (n = 5, grey bars). Mice culled at 16 hr after the BRDU injection and BM harvested. (<bold>E</bold>) Percentage of BRDU positivity in HSPC, MDP, cMoP, GMP, total monocytes, Ly6C-high monocytes, and Ly6C-low monocytes. (<bold>F</bold>) Representative histogram of BRDU expression in HSPC at baseline (blue) or after 2× topical R848 (magenta). (<bold>G</bold>) Percentage of Sca1 positivity in total monocytes, Ly6C-high monocytes and Ly6C-low monocytes in the BM. (<bold>H</bold>) BALB/c mice (n = 3) received four treatments with topical R848. Blood counts for Ly6C-high monocytes (white bars), Ly6C-low monocytes (grey bars), and lymphocytes were monitored at the indicated time points after the cessation of treatment. Data representative of two independent experiments (except <bold>A</bold> and <bold>H</bold>). Two-way ANOVA with Tukey’s multiple comparison for time-course experiments (<bold>A–C, H</bold>); unpaired <italic>t</italic>-test (<bold>E, G</bold>). Data are the mean ± SEM; only significant p-values are indicated; *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>FACS raw data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85647-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85647-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Bone marrow (BM) gating strategy.</title><p>(<bold>A, B</bold>) HSC-SCL-Cre-ERT;R26R-EYFP mice (n = 4 per group) were treated for five consecutive days with tamoxifen (4 mg/100 μl) by oral gavage. Three days after the tamoxifen administration, the left ears were treated topically 4× with R848 or left untreated. (<bold>A</bold>) Gating strategy for YFP+ HSCs in BM. HSCs are excluded for doublets using side scatter area and side scatter height prior and gated lineage negative (B220, CD5, CD4, CD8, TER119, and GR-1). HSCs were then defined as CD117+Sca-1+CD150+CD48-. EYFP was then gated to determine recombination efficiency. (<bold>B</bold>) Percentage of EYFP+ HSCs within the HSCs in the BM after tamoxifen and 4xR848 treatment (R848 group, blue squares) or tamoxifen only (no R848 group, open circles). Representative of two independent experiments. (<bold>C</bold>) Gating strategy for BM cells. All populations are gated lineage-negative (CD3, B220, Ly6G, CD49b). HSPC: CD115-neg, c-kit+, Sca-1-neg; MDP: CD115+, c-Kit+, Ly6C-low; cMoP: CD115+, c-Kit+, Ly6C-high, Flt3-neg; GMP: CD115-neg, cKit+, Sca-1-neg, CD16/32+ , Ly6C-low; CMP: CD115-neg, cKit+, Sca-1-neg, CD16/32-neg, Ly6C-low; GP: CD115-neg, cKit+, Sca-1-neg, CD16/32+ , Ly6C-high; Ly6C-high monocytes: CD115+, c-Kit-neg, Ly6C-high; Ly6C-low monocytes: CD115+, c-Kit-neg, Ly6C-low. HSPC: haematopoietic stem and progenitor cells; CMP: common myeloid progenitor; MDP: monocyte-dendritic precursor; GMP: granulocyte-monocyte progenitor; cMoP: common monocyte progenitor; CDP: common dendritic progenitor; MP: monocyte-committed progenitor; GP: granulocyte-committed progenitor.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85647-fig4-figsupp1-v2.tif"/></fig></fig-group><p>Monocytes are derived from a defined program of progenitor differentiation in the BM outlined in <xref ref-type="fig" rid="fig4">Figure 4D</xref>. To investigate this pathway, we assessed proliferation of BM progenitor cells using bromodeoxyuridine (BRDU) pulse-chase experiments. When we examined BRDU incorporation in progenitor cells (gated strategy in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), we found that R848 dramatically increased the percentage of HSPCs in cell cycle from ~4.6% to ~45.6% (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>). Consistent with the peripheral blood data showing that TLR7 activation targets the monocytes and does not affect the granulocyte lineage, there was a significant increase in BRDU positivity among MDPs and cMoPs, but not in GMPs (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Unsurprisingly, the mature BM monocyte population also showed increased BRDU incorporation (<xref ref-type="fig" rid="fig4">Figure 4E</xref>) and this was present in both monocyte subpopulations indicating that the effects of TLR7 activation were not limited to the Ly6C-low cells (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Of note, the R848-induced bone marrow monocytes also upregulated expression of the stem cell antigen 1 (Sca1) (<xref ref-type="fig" rid="fig4">Figure 4G</xref>), a feature consistent with an emergency myelopoiesis (<xref ref-type="bibr" rid="bib4">Askenase et al., 2015</xref>).</p><p>Given the dramatic increase in the proportion of normally quiescent HSPCs in cell cycle, we hypothesised that R848-induced monocytosis would persist for a considerable period after cessation of the treatment. Indeed, after four topical R848 treatments, it took at least 17 d for total monocyte counts to return to pre-bleed levels (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). The monocyte changes were accompanied by a decrease in blood lymphocyte numbers, which reached pre-treatment levels by day 10 (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). We therefore concluded that cutaneous TLR7 activation can bypass the splenic reservoir and can instruct the BM HSPCs to proliferate and differentiate predominantly along the monocytic pathway triggering an emergency myelopoiesis.</p></sec><sec id="s2-5"><title>Topical R848 accelerates the differentiation of Ly6C-high monocytes to macrophages</title><p>Under homeostatic conditions, Ly6C-high monocytes have been shown to be obligate precursors for Ly6C-low monocytes in the blood (<xref ref-type="bibr" rid="bib48">Mildner et al., 2017</xref>). As both BM monocyte subpopulations displayed increased proliferation after topical R848, we questioned whether the Ly6C-low monocytosis under the pathological setting of our experimental model was the result of increased Ly6C-high monocyte conversion or of enhanced egression of Ly6C-low monocytes emerging from the BM as a separate lineage. To answer this question, we utilised an antibody-mediated depletion strategy via injection of an Fc-chimeric mouse anti-GR1. In naïve mice, this antibody fully depletes blood Ly6C-high monocytes by 24 hr post-injection, leaving Ly6C-low cells unaffected (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). We then administrated this depleting antibody or an anti-FITC isotype control for three consecutive days to R848-treated mice, starting simultaneously with the third R848 treatment at day 6. As expected in untreated mice, the Fc-chimeric mouse anti-GR1 antibody reduced the Ly6C-high monocyte counts to undetectable levels (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Importantly, in R848-treated mice the Ly6C-high monocyte depletion due to the Fc-chimeric mouse anti-GR1 antibody abrogated the monocytosis, whilst the isotype control had no effect (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). These data suggest that the expanded Ly6C-low monocyte population is predominantly, if not entirely, derived from the Ly6C-high monocyte population and not from an expansion of a separate lineage in the BM.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Topical R848 drives Ly6C-high monocyte differentiation to intravascular and tissue macrophages.</title><p>(<bold>A</bold>) C57BL/6 mice were injected intraperitoneally (IP) with either anti-GR1 antibody (n = 3, red squares) or matched isotype control (n = 3, black triangles). Blood Ly6C-high and Ly6C-low monocyte counts (upper panels) and representative flow cytometry plots (bottom panels) are shown at 24 hr post-injection. (<bold>B</bold>) C57BL/6 mice were treated with combinations of topical R848 and IP anti-GR1 antibody or matched isotype control, with the antibody injected daily for three consecutive days starting 1 hr prior to the third R848 treatment (day 6). The groups were isotype control and R848 (n = 4, red triangle), anti-GR1 and R848 (n = 4, blue squares), and anti-GR1 alone (n = 4, black circles). Blood counts for total monocytes, Ly6C-high monocytes, and Ly6C-low monocytes at baseline and on the indicated days are shown. Statistics compare anti-GR1+R848 to isotype +R848. (<bold>C</bold>) C57BL/6 mice received four treatments with topical R848 (n = 4 per group, grey bars) or acetone (n = 4 per group, white bars). Immunofluorescent staining for CD68 (green) and nuclei (grey) was performed on tissue sections from lung, liver, and kidneys. Staining was quantified as mean CD68+ cells per field. (<bold>D</bold>) C57BL/6 mice (n = 4) received six treatments with topical R848. Kidney sections were stained for CD43 (red), F4/80 (green), and nuclei (grey). A representative tile scan is shown. Data representative of two independent experiments (except <bold>D</bold>). Time-course experiments analysed with two-way ANOVA with Tukey’s multiple-comparison used to compare between groups at a given time point (<bold>B</bold>); comparison of two groups at a single time point calculated using unpaired <italic>t</italic>-test (<bold>C</bold>). Data are the mean ± SEM; only significant p-values are indicated; *p&lt;0.05.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>FACS raw data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85647-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85647-fig5-v2.tif"/></fig><p>Ly6C-low blood monocytes are viewed as intravascular ‘blood macrophages’ due to their transcriptional similarity to tissue macrophages (<xref ref-type="bibr" rid="bib48">Mildner et al., 2017</xref>). Therefore, we reasoned that the cutaneous R848 treatment may be driving an accelerated macrophage differentiation program in Ly6C-high monocytes and thereby also promoting macrophage infiltration into tissue. To confirm this, tissue sections from lungs, liver, and kidneys of R848-treated mice were stained with an anti-CD68 antibody. A significant increase of CD68+ cells per field was observed in all these organs (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). In the kidney, we also used a combination of CD43 and F4/80 staining to distinguish intravascular CD43-high non-classical monocytes from F4/80-high CD43-negative tissue macrophages (<xref ref-type="bibr" rid="bib41">Kuriakose et al., 2019</xref>). Using this strategy, we found that CD43-positive cells were confined to the vasculature of the glomeruli, while F4/80-high macrophages were mainly located in the medulla (<xref ref-type="fig" rid="fig5">Figure 5D</xref>), findings consistent with the different roles of these two myeloid subpopulations.</p><p>Together these data indicate that cutaneous TLR7 activation triggers the egression from the BM of emergency Ly6C-high monocytes that undergo an accelerated macrophage differentiation, both patrolling the vascular lumen as Ly6C-low monocytes and also directly invading different organs as blood-derived tissue macrophages. As the Ly6C-low population remains in the intravascular space, this would explain the progressing switch in the Ly6C-high and Ly6C-low monocyte ratio (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p></sec><sec id="s2-6"><title>Topical R848 triggers a CCR2-independent myeloid response</title><p>Under steady-state conditions, the monocyte release from the BM is orchestrated by CCR2 and CX3CR1 (<xref ref-type="bibr" rid="bib42">Landsman et al., 2009</xref>; <xref ref-type="bibr" rid="bib70">Tsou et al., 2007</xref>). We investigated whether this was also true for the R848-induced myelopoiesis using <italic>Ccr2<sup>RFP/RFP</sup></italic> knock-in mice (<xref ref-type="bibr" rid="bib57">Saederup et al., 2010</xref>). As previously reported (<xref ref-type="bibr" rid="bib70">Tsou et al., 2007</xref>), at baseline CCR2-deficient mice had less blood monocytes than the WT animals due to a failure of Ly6C-high monocytes to egress from the BM (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). After topical R848 treatments, monocytosis was present in both strains and the Ly6C-low monocyte fold increase from baseline was even higher in the mice lacking CCR2 (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Consistent with the notion that the R848-driven monocyte response bypassed the conventional pathways, we found a similar increase of CD68+ cells per field in the kidney and lung of the CCR2-deficient mice, indicating that different signals also orchestrated the monocyte extravasation into the tissues (<xref ref-type="fig" rid="fig6">Figure 6C</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Immature monocytes egress from the bone marrow (BM) independently of CCR2.</title><p>(<bold>A, B</bold>) C57BL/6 mice (n = 4, black triangles) or Ccr2RFP/RFP mice (n = 6, red squares) were treated topically six times with R848. (<bold>A</bold>) Blood counts for total monocytes, Ly6C-high and Ly6C-low monocytes at 24 hr after each treatment are shown. (<bold>B</bold>) Fold change of monocyte subpopulations versus baseline after 6× R848 treatments. (<bold>C</bold>) C57BL/6 mice or Ccr2RFP/RFP mice were either naive (WT n = 4, Ccr2RFP/RFP n = 4, grey bars) or received six R848 treatments (WT n = 4, Ccr2RFP/RFP n = 4, red bars). Immunofluorescent staining for CD68 (green) and nuclei (grey) was performed on tissue sections from lung and kidneys. Staining was quantified as mean CD68+ cells per field. Data representative of two (<bold>C</bold>) or four (<bold>A, B</bold>) independent experiments. Time-course experiments analysed using two-way ANOVA with Tukey’s multiple-comparison test to compare between time points (<bold>A</bold>); for a single time point one-way ANOVA with Bonferroni’s multiple-comparison test for &gt;2 groups (<bold>B, C</bold>). Data are the mean ± SEM; only significant p-values are indicated; *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>FACS raw data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85647-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85647-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>R848-induced myeloid response is independent from CX3CR1 and vascular permeability.</title><p>(<bold>A</bold>) C57BL/6 mice (n = 3, black lines) or <italic>Cx3cr1<sup>GFP/GFP</sup></italic> (n = 3, orange lines) were treated topically four times with R848. Blood counts for total monocytes, Ly6C-high monocytes, Ly6C-low monocytes, and the fold change of monocyte subpopulations after four treatments versus baseline. (<bold>B, C</bold>) BALB/c mice were naive (n = 5) or treated topically four times with R848 (n = 6). 1 mg Evans Blue was injected intravenously (IV) at 24 hr after the final R848 treatment. (<bold>B</bold>) Quantity of Evans Blue per ear is shown for naive mice (white bars), the R848-treated ear (red bars), and the contralateral ear (grey bars), along with representative photographs. (<bold>C</bold>) Evans Blue is quantified as µg per tibia in naïve and R848-treated mice. Data representative of two independent experiments. Time-course experiments analysed using two-way ANOVA with Tukey’s multiple-comparison test to compare between time points (<bold>A</bold>); fold change data analysed using unpaired <italic>t</italic>-test (<bold>A</bold>); two groups at a single time point compared using unpaired <italic>t</italic>-test (<bold>C</bold>); one-way ANOVA with Bonferroni’s multiple-comparison test for &gt;2 groups at a single time point (<bold>B</bold>). Data are the mean ± SEM; only significant p-values are indicated; *p&lt;0.05, ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85647-fig6-figsupp1-v2.tif"/></fig></fig-group><p>We next investigated CX3CR1, which has been shown to regulate peripheral levels of Ly6C-low monocytes (<xref ref-type="bibr" rid="bib42">Landsman et al., 2009</xref>), using the <italic>Cx3cr1<sup>GFP/GFP</sup></italic> knock-in mouse. At baseline, in the <italic>Cx3cr1<sup>GFP/GFP</sup></italic> animals the peripheral Ly6C-low monocyte levels were approximately 50% of those in WT mice, as previously reported (<xref ref-type="bibr" rid="bib42">Landsman et al., 2009</xref>). However, after 4× topical R848 treatments the <italic>Cx3cr1<sup>GFP/GFP</sup></italic> mice developed a monocytosis that was skewed towards Ly6C-low subpopulation as in WT mice (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>), demonstrating that CX3CR1 is dispensable for R848-driven myelopoiesis. Given the independence of the monocyte egress from prototypical signals, we explored whether topical R848 could be promoting monocyte or haemopoietic progenitor mobilisation in a non-targeted manner by increasing vascular permeability. We injected IV into naïve and R848-treated mice the Evans Blue dye that binds to albumin and would leak into peripheral tissues during situations of decreased vascular integrity (<xref ref-type="bibr" rid="bib56">Radu and Chernoff, 2013</xref>). We found that the Evans Blue amount in the ears from naïve mice was equal to that present in R848-treated ears and the contralateral ears of R848-treated mice (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). In addition, there was no increase in BM vascular permeability as assessed by Evans Blue quantity per tibia (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). Thus, these findings demonstrate that the cutaneous TLR7 activation was able to stimulate the egression from the BM of monocytes circumventing the requirement of homeostatic cues like CCR2 or CX3CR1 by activating emergency pathways.</p></sec><sec id="s2-7"><title>The R848-induced emergency myeloid cells enhance viral control and limit the disease severity</title><p>As the BM egression of R848-induced monocytes occurred independently from the conventional regulatory mechanisms, we hypothesised these monocytes could be phenotypically and functionally distinct. Using the <italic>Cx3cr1</italic><sup>GFP/-</sup> mouse, Ly6C-low monocytes were visualised by intravital microscopy in the contralateral ear of mice treated topically 4× with R848. We observed a dramatic increase (~10-fold) in intravascular CX3CR1-GFP+ monocytes in the R848-treated group (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). These monocytes appeared to be rolling on the vessel wall, indicating an activated phenotype (<xref ref-type="video" rid="video1">Video 1</xref>). To confirm this, we comprehensively phenotyped the blood monocytes by flow cytometry. Consistent with the phenotype of the R848-induced bone marrow monocytes (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), both blood subpopulations displayed expression of Sca1 (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). In addition, both monocyte subpopulations expressed less F4/80 and more CD115 (<xref ref-type="fig" rid="fig7">Figure 7B and C</xref>), suggesting an immature phenotype and a recent dependence on M-CSF. These changes were particularly pronounced in the Ly6C-low population, which appeared both activated and immature as reflected by the upregulation of CXCR4, CD11c, CD11a, and CD62L and the downregulation of CCR2 (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Most notably, increased CXCR4 and decreased CCR2 expression phenocopy the changes seen in transitional BM pre-monocytes (<xref ref-type="bibr" rid="bib13">Chong et al., 2016</xref>), which are not normally found in the blood, suggesting the premature egress of an emergency population. We next explored whether the R848-induced monocytes were also functionally impaired. We isolated BM monocytes from R848-treated and untreated mice and challenged them in vitro with R848 or LPS. We found that the R848-treated monocytes had a reduced cytokine response when rechallenged with the same TLR7 agonist but not with a different TLR stimulus (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>), suggesting a pathway-specific adaptation in the monocytes derived from the R848-exposed HSCs.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>R848-induced emergency monocytes have antiviral effects in the lung.</title><p>(<bold>A–C</bold>) C57BL/6 mice were either naive (n = 4, black circles) or treated four times with topical R848 (n = 4, red squares). (<bold>A</bold>) Percentage of cells positive for Sca-1 and representative histograms in blood Ly6C-high and Ly6C-low monocytes from naive mice (grey) or R848-treated mice (red). (<bold>B</bold>) Blood Ly6C-high and Ly6C-low monocytes were gated by flow cytometry and surface expression of the indicated proteins was quantified and expressed as MFI, normalised to the mean of the naive group. (<bold>C</bold>) Representative histograms of CCR2, F4/80, and CD115 staining in blood Ly6C-high and Ly6C-low monocytes. (<bold>D</bold>) Percentage of original weight (left panel) and lung viral load (right panel) in C57BL/6 mice (n = 8/group) pretreated five times with or without topical R848 infected intranasally with the influenza virus strains X31. Lung viral load at day 7 post inoculation was measured by quantification of matrix X31 gene copies in whole lung tissues. (<bold>E</bold>) Lung viral load after respiratory syncytial virus (RSV) infection in C57BL/6 mice (n = 6–7/group) pretreated or not with topical R848 (five times) was determined by quantification of viral L gene copies in lung tissues at day 4 post inoculation. Data representative of two independent experiments. Statistical analysis using unpaired <italic>t</italic>-test (<bold>A, B; D</bold> right panel, <bold>E</bold>); two-way ANOVA with Bonferroni’s post hoc test (<bold>D</bold>, left panel) Data are the mean ± SEM; only significant p-values are indicated; *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>FACS raw data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-85647-fig7-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85647-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>R848-induced monocytes are activated and functionally impaired.</title><p>(<bold>A</bold>) <italic>Cx3cr1<sup>GFP/+</sup></italic> mice were treated topically four times with R848 (n = 5, grey bars) or acetone (n = 3 white bars) on the right ear. 24 hr after the last treatment, mice were anaesthetised and the contralateral ear was visualised using intravital microscopy. Representative images are shown of the contralateral ears (red = dextran, green = CX3CR1-GFP). Non-classical monocytes are quantified as intravascular GFP+ cells per minute (left panel). (<bold>B</bold>) C57BL/6 mice were treated topically four times with 100 μg of R848. Bone marrow (BM)-sorted monocytes (four biological replicates per group) were plated in vitro at a concentration of 1 × 10<sup>6</sup> per ml and restimulated overnight with 100 μg/ml of R848 or 1 μg/ml of LPS. Unstimulated monocytes were used naïve controls. Cytokines in the supernatant were quantified using a Legendplex Mix and expressed as pg/ml. Data representative of two independent experiments. Statistical analysis using unpaired <italic>t</italic>-test to compare two groups (<bold>A</bold>) and two-way ANOVA with Bonferroni’s multiple-comparison test for &gt;2 groups (<bold>B</bold>). Data are the mean ± SEM; only significant p-values are indicated; * p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85647-fig7-figsupp1-v2.tif"/></fig></fig-group><media mimetype="video" mime-subtype="mp4" xlink:href="elife-85647-video1.mp4" id="video1"><label>Video 1.</label><caption><title><italic>Cx3cr1<sup>GFP/+</sup></italic> mice were treated topically on the right ear for four times with R848 (panel on the right) or acetone (panel on the left).</title><p>24 hr after the last treatment, the mice were anaesthetised and the contralateral ear was visualised using intravital microscopy (red = dextran, green = CX3CR1-GFP).</p></caption></media><p>As the epithelial R848 applications promoted the migration and macrophage differentiation of Ly6C-high monocytes in peripheral organs like the lungs (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), we next evaluated their contribution to control viral infections. We first infected R848-treated and control mice with the low pathogenicity H3N2 influenza strain X31 (<xref ref-type="bibr" rid="bib20">Davidson et al., 2014</xref>). We found that the animals with the myeloid response showed reduced weight loss compared to untreated mice (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Consistent with the change in weight loss, the lung viral load, measured by expression of the influenza X31 matrix gene, was decreased in R848-treated mice (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Similarly, the viral replication after infection with the RSV, an RNA virus responsible for infant hospitalisations in the developed world, was limited in R848-treated mice (<xref ref-type="fig" rid="fig7">Figure 7E</xref>).</p><p>Monocytes have previously been shown to have a beneficial antiviral effect in the lungs (<xref ref-type="bibr" rid="bib27">Goritzka et al., 2015</xref>). Together our findings indicate that the extravasation of monocytes into the lungs as a result of the emergency monopoiesis triggered by cutaneous TLR7 activation is associated with limited viral replication and dampened disease severity. Altogether, this confirms the protective effect mediated by innate immunity even if the encounter with a pathogen-derived product occurs at a distant site.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Increased BM output of inflammatory cells, known as ‘emergency myelopoiesis,’ is a critical feature of the host response to injury or infection. This process can be driven by systemic inflammatory factors and/or pathogen-derived products acting on precursor cells (<xref ref-type="bibr" rid="bib69">Takizawa et al., 2012</xref>). Herein, we demonstrate that activation of TLR7 at the epithelial barrier of the skin and gut launches a specific and distinct monopoiesis response which does not occur after systemic TLR7 activation or activation of other TLRs. It is characterised by a rapid and dramatic increase of blood monocytes that egress from the BM bypassing the requirement of homeostatic cues like CCR2 or CX3CR1. The TLR7-induced monocytes appear to be immature and programmed to differentiate into macrophages, both surveying the endothelial integrity as Ly6C-low monocytes and trans-migrating into different organs to complement tissue resident macrophages. The response is orchestrated by BM-derived myeloid cells capable of transmitting the signals to the BM HSPCs independently from some of the well-known cytokines such type I and type II IFNs (summarised in <xref ref-type="fig" rid="fig8">Figure 8</xref>). Collectively our findings define the unique features of the BM myeloid response triggered by single-stranded RNA viruses on entering the epithelial barrier, a condition most likely occurring in infections with arboviruses and coronaviruses.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Repetitive application of a TLR7 agonist (R848) to the skin activates tissue macrophages which signal to the bone marrow to drive the expansion of haematopoietic stem and progenitor cells (HSPCs) and their differentiation into monocytes.</title><p>These Ly6C-high monocytes have an immature phenotype and egress from the bone marrow independently of CCR2. Subsequently, Ly6C-high monocytes differentiate into Ly6C-low blood monocytes and into tissue macrophages in multiple organs such as liver, lung, and kidneys. When challenged with a secondary viral stimulus such as influenza or respiratory syncytial virus (RSV) infection, the emergency myelopoiesis is associated with reduced disease severity.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85647-fig8-v2.tif"/></fig><p>One of the key observations of our study is the unicity of the initial peripheral signal that is specific to, and shared between, epithelial barriers. Although the detailed mechanisms underlying this specificity remain to be defined, the canonical role of TLR7 in sensing viral ssRNA makes it evolutionarily logical for the response to be specific to epithelial barriers, which must be breached for infection to be established. The skin, lungs, and the gut are similar in their constant exposure to mechanical trauma and a wide range of pathogens. To manage these insults, all these sites are equipped with an immune surveillance network comprising tissue resident macrophages, dendritic cells, and mast cells, as well as resident lymphocytes such as γδ T cells and innate lymphoid cells. Notably, in the skin and gut a subset of macrophages are replenished by circulating monocytes (<xref ref-type="bibr" rid="bib7">Bain et al., 2014</xref>; <xref ref-type="bibr" rid="bib40">Kolter et al., 2019</xref>), unlike in other tissues where macrophages are embryonically derived, proliferate in situ and are only replenished by circulating monocytes after a severe insult (<xref ref-type="bibr" rid="bib26">Ginhoux and Guilliams, 2016</xref>). Interestingly, TLR7 hyperactivation has been shown to drive a myeloid cell expansion in other settings, such as the transgenic overexpression of TLR7 in the TLR7.1 mouse (<xref ref-type="bibr" rid="bib21">Deane et al., 2007</xref>). However, in these models the monocyte response appears to be driven by the extramedullary haematopoiesis in the spleen, whilst in our experimental model the BM is the only source of the myeloid expansion demonstrating the specificity of the peripheral cues induced by TLR7 activation in the skin and gut.</p><p>The monocytosis following topical R848 applications is accompanied by a dramatic expansion of HSPCs and monocyte progenitor cells in the BM and the egression in the peripheral blood of transitional BM pre-monocytes. Others have previously described a rapid expansion of phenotypically distinct Ly6C-high monocytes following infections with multiple intestinal pathogens, both parasitic and bacterial (<xref ref-type="bibr" rid="bib1">Abidin et al., 2017</xref>; <xref ref-type="bibr" rid="bib4">Askenase et al., 2015</xref>). In concordance with previous reports, we found that the expanded BM monocyte population expressed high levels of Sca-1 (<xref ref-type="bibr" rid="bib4">Askenase et al., 2015</xref>). However, in our model the induced monocytosis was independent of both type I and type II IFNs, indicating that a different priming mechanism had occurred. One interesting possibility is the type III IFN, which is increasingly recognised as an inducer of local antiviral immunity at epithelial barriers (<xref ref-type="bibr" rid="bib43">Lazear et al., 2015</xref>; <xref ref-type="bibr" rid="bib74">Wack et al., 2015</xref>) and may have a still unrecognised role in the regulation of monocyte progenitors. It is also possible that CSF-1 signalling is involved in the monocyte expansion observed in our experimental model, given the upregulation of the CSF1R (CD115) on the R848-expanded monocytes. Administration of recombinant CSF-1 can expand blood monocytes 5- to 10-fold after 10 d and requires repeated dosing (<xref ref-type="bibr" rid="bib72">Ulich et al., 1990</xref>). However, it remains puzzling why CSF-1 secretion would only be initiated at epithelial barriers and not after systemic activation of TLR7 considering that this can induce extramedullary haematopoiesis in the spleen (<xref ref-type="bibr" rid="bib21">Deane et al., 2007</xref>).</p><p>A striking feature of our model is the accelerated differentiation of Ly6C-high to Ly6C-low monocytes. Recent work has suggested that TLR7 activation of Ly6C-high monocytes using topical IMQ or in vitro can directly promote their conversion to Ly6C-low monocytes (<xref ref-type="bibr" rid="bib24">Gamrekelashvili et al., 2020</xref>). However, while we agree that topical TLR7 activation can accelerate monocyte conversion, this appears to be an indirect effect driven by a secondary stimulus, as IV or IP administration of R848 did not result in an obvious monocyte ratio switch. As part of the enhanced differentiation program induced by topical R848, Ly6C-high monocytes also infiltrated peripheral organs and markedly increased the number of tissue macrophages with probably different consequences according to the organ. Global TLR activation using the TLR7.1 transgenic mouse has previously been shown to drive macrophage differentiation to inflammatory hemophagocytic macrophages which infiltrate the spleen and caused anaemia and thrombocytopenia (<xref ref-type="bibr" rid="bib3">Akilesh et al., 2019</xref>). However, unlike the phenotype described here, this process was due to direct TLR7 activation in the BM and could be recapitulated using multiple daily I.P injection of R848, something that we did not detect using a less strong stimulation. In addition, in the paper by <xref ref-type="bibr" rid="bib3">Akilesh et al., 2019</xref> the generation of hemophagocytes could also be promoted by TLR9 activation, whereas we saw no effects of topical CpG application on peripheral monocytes. Whilst it is difficult to reconcile the different findings, one could argue that the TLR7.1 transgenic mouse and the hyper-stimulation applied by Akilesh et al. in their model may recapitulate extreme phenotypes observed in the macrophage activation syndrome (MAS), a life-threatening complication of rheumatological diseases, whilst our experimental models mimic more closely the BM response to common single-stranded RNA viral infections.</p><p>The BM egression of monocytes in steady-steady conditions and during emergency myelopoiesis in response to inflammation and/or infections, including <italic>Toxoplasma gondii</italic> and <italic>Listeria monocytogenes</italic>, has been reported to depend on CCR2 expression (<xref ref-type="bibr" rid="bib29">Grainger et al., 2013</xref>; <xref ref-type="bibr" rid="bib61">Serbina and Pamer, 2006</xref>; <xref ref-type="bibr" rid="bib62">Serbina et al., 2009</xref>) and this has become an accepted dogma in the literature. However, our findings demonstrate unequivocally that topical TLR7 application generates monocytes which are released from the BM in a CCR2-independent process. To our knowledge, the only other context in which this has been shown is during La Crosse virus infection, which interestingly has an ssRNA genome and is detected via TLR7 (<xref ref-type="bibr" rid="bib76">Winkler et al., 2018</xref>). Consistent with a CCR2-independent egress, the R848-induced peripheral blood monocytes have low CCR2 expression and have an immature CXCR4-high, F4/80-low phenotype reminiscent of BM pre-monocytes (<xref ref-type="bibr" rid="bib13">Chong et al., 2016</xref>). Under homeostatic conditions, CXCR4 and CCR2 play antagonistic roles dictating the respective retention or release of Ly6C-high monocytes from the BM (<xref ref-type="bibr" rid="bib39">Jung et al., 2015</xref>). Therefore, the presence of upregulated CXCR4 on blood monocytes potentially indicates their premature release to meet increased demand via a bypass of the CCR2/CXCR4 axis. Of note, a potentially similar phenomenon has been suggested during SARS-CoV-2 infection, based on the presence of proliferation markers on blood monocytes (<xref ref-type="bibr" rid="bib46">Mann et al., 2020</xref>). Given that SARS-CoV-2 has an ssRNA genome, further work is required to determine if our findings are applicable in this setting.</p><p>Another striking feature of our model was the accelerated extravasation of the immature R848-induced monocytes into multiple organs. Again, this egression occurred independently from conventional pathways like CCR2/CCL2 and was not associated with any obvious evidence of organ inflammation or damage, suggesting a distinct pathway. Consistent with the notion and previous data (<xref ref-type="bibr" rid="bib27">Goritzka et al., 2015</xref>) that an early recruitment of Ly6C-high monocytes into the lung is a beneficial feature of the host innate immune response to virus infection, we found that the influx of R848-induced emergency myeloid cells restricted RSV and influenza virus replication and dampened disease severity. Similarly, monocyte-derived cells have been shown to limit HSV-2 and HSV-1 replication in the vaginal tract and in the cornea, respectively (<xref ref-type="bibr" rid="bib15">Conrady et al., 2013</xref>; <xref ref-type="bibr" rid="bib37">Iijima et al., 2011</xref>), indicating that these cells play a key role in the resistance to viruses together with the type I IFNs. Notably, the fact that the monocytosis persisted long after the TLR7 stimulation at the epithelial barrier had ceased would suggest that the protective effects provided by these cells may prolong the antiviral effect of the type I IFNs. However, blood-derived tissue macrophages can also induce tissue damage. For example, inflammatory Ly6C-high monocytes have been shown to contribute to lung pathology in a model of influenza virus infection (<xref ref-type="bibr" rid="bib20">Davidson et al., 2014</xref>; <xref ref-type="bibr" rid="bib34">Herold et al., 2008</xref>; <xref ref-type="bibr" rid="bib45">Lin et al., 2008</xref>), most likely recapitulating the pathology that occurs in severe infection if the initial innate response is dysregulated. A similar pattern has also been reported during SARS-CoV-2 infection where dynamic changes in the monocyte response have been correlated with COVID-19 disease severity (<xref ref-type="bibr" rid="bib60">Schulte-Schrepping et al., 2020</xref>). Therefore, recruitment of antiviral monocytes during lung infections must be carefully balanced to reduce viral load but not allow excessive cell infiltration that can cause tissue damage.</p><p>In summary, the work presented here elucidates a novel pathway of emergency myelopoiesis which is uniquely activated by TLR7-expressing macrophages at epithelial barriers. Unlike in other settings, this is due to a specific expansion of the monocyte lineage from BM progenitors, is CCR2-independent, and releases atypical pre-monocytes in the periphery. This emergency myeloid population is pushed towards a macrophage differentiation pathway which results in a predominance of Ly6C-low patrolling monocytes in the blood and a simultaneous infiltration of inflammatory macrophages into peripheral organs. Together these data challenge the dogma on how monocytes are produced during viral infections occurring at peripheral sites and highlight their contribution to the initial antiviral immunity.</p><sec id="s3-1"><title>Limitations of the study</title><p>While this study has revealed a novel pathway of emergency myelopoiesis uniquely triggered by TLR7 activation at epithelial barriers, it has a few limitations. First, we did not identify the mechanism(s) for the remote activation of monocytes. We assume that a soluble factor mediates this effect, but the nature of this soluble factor remains unclear. Additionally, whilst our study indicates that skin myeloid cells are responsible for this expansion of the monocyte lineage from BM progenitors, we could not pinpoint to a specific skin myeloid cell type. Furthermore, while our experiments demonstrate a CCR2-independent egression of BM immature monocytes as well as CCR2-independent migration of the Ly6C-high monocytes into different organs, we did not define the distinct pathways driving these processes. Moreover, how the R848-induced emergency myeloid cells modulate the lung anti-viral response remains a speculation and further studies will be needed to address these points.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse Ly6G FITC (1A8)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 127606</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse MHC-II FITC (M5/114.15.2)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 107606</td><td align="left" valign="bottom">Flow (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse Ly6C PerCP-Cy5.5 (HK1.4)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 128012</td><td align="left" valign="bottom">Flow (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse Ly6C Brilliant Violet 605 (HK1.4)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 128036</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD11b PE-Cy7 (M1/70)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 101216</td><td align="left" valign="bottom">Flow (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD11b APC (M1/70)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 101212</td><td align="left" valign="bottom">Flow (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD115 PE (AFS98)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 135506</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD115 APC (AFS98)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 135510</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse B220 Brilliant Violet 605 (RA3-6B2)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 103244</td><td align="left" valign="bottom">Flow (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse B220 FITC (RA3-6B2)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 553087</td><td align="left" valign="bottom">Flow (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Hamster anti-mouse CD3e Brilliant Violet 711 (145-2C11)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100349</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Hamster anti-mouse CD3e FITC (145-2C11)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 553062</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD11a APC (M17/4)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 101120</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD117 PE-Cy7 (2B8)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 105814</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD11b PerCP-Cy5.5 (M1/70)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 101228</td><td align="left" valign="bottom">Flow (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD135 Brilliant Violet 421 (A2F10.1)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 135315</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse Sca1 Brilliant Violet 711 (D7)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 108131</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD16/CD32 APC-Cy7 (93)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 101328</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD135 APC (A2F10.1)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 135310</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD49b FITC (DX5)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 553857</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Hamster anti-mouse CD11c APC (HL3)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 550261</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD45 APC-eFluor 780 (30-F11)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 47-0451-82</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse Ly6G Brilliant Violet 421 (1A8)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 127628</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse F4/80 Brilliant Violet 785 (BM8)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 123141</td><td align="left" valign="bottom">Flow (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse F4/80 Alexa Fluor 488 (BM8)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 123120</td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse MHC-II PerCP eFluor710 (M5/114.15.2)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 46-5321-82</td><td align="left" valign="bottom">Flow (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse Sca1 PE-Dazzle 594 (D7)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 108138</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD43 Alexa Fluor 700 (S11)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 143214</td><td align="left" valign="bottom">Flow (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD43</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 143202</td><td align="left" valign="bottom">IF (1:50)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-Art IgG (H+L) Cross-Adsorbed secondary antibody, Alexa-Fluor 555</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# A-21434</td><td align="left" valign="bottom">IF (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CXCR4 Alexa Fluor 647 (L276F12)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 146504</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CCR2 Brilliant Violet 510 (SA203G11)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 150617</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Hamster anti-mouse CD11c PE-Cy7 (HL3)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 561022</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse Ly6C eFluor450 (HK1.4)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 48-5932-82</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD68 Alexa Fluor 488 (FA-11)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 137012</td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse Ly6G eFluor450 (1A8)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 48-9668-82</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse B220 PE-Cy5 (RA3-6B2)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 103210</td><td align="left" valign="bottom">Flow (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD4 PE-Cy5 (RM4-5)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100513</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD5 PE-Cy5 (53-7.3)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100604</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD8 PE-Cy5 (53-6.7)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 100710</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse TER119 PE-Cy5 (TER119)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 116210</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse GR1 PE-Cy5 (RB6-8C5)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 108410</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD150 PE-Cy7 (TC15-12F12.2)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 115914</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse CD117 APC eFluro780 (2B8)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 47-1171-82</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse Sca1 BV785 (D7)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 108139</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Hamster anti-mouse CD48 APC (HM48-1)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 103412</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse Ly6G (1A8, mouse chimeric)</td><td align="left" valign="bottom">Absolute Antibody</td><td align="left" valign="bottom">Cat# Ab00295-2.3</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse GR1 (RB6-8C5, mouse chimeric)</td><td align="left" valign="bottom">Absolute Antibody</td><td align="left" valign="bottom">Cat# Ab01030-2.0</td><td align="left" valign="bottom">Flow (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat anti-mouse IL-6R (15A7)</td><td align="left" valign="bottom">BioXcell</td><td align="left" valign="bottom">Cat# BE0047</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rat IgG2b isotype control, anti-keyhole limpet hemocyanin (LTF-2)</td><td align="left" valign="bottom">BioXcell</td><td align="left" valign="bottom">Cat# BE0090</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, , recombinant protein</td><td align="left" valign="bottom">R848 (water soluble)</td><td align="left" valign="bottom">Invivogen</td><td align="left" valign="bottom">tlrl-r848</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, , recombinant protein</td><td align="left" valign="bottom">R848</td><td align="left" valign="bottom">Enzo</td><td align="left" valign="bottom">ALX-420-038M025</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, , recombinant protein</td><td align="left" valign="bottom">Poly(I:C) (LMW)</td><td align="left" valign="bottom">Invivogen</td><td align="left" valign="bottom">tlrl-picw</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, , recombinant protein</td><td align="left" valign="bottom">CpG (ODN 2395)</td><td align="left" valign="bottom">Invivogen</td><td align="left" valign="bottom">tlrl-2395</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, , recombinant protein</td><td align="left" valign="bottom">LPS (<italic>E. coli</italic> 055:B5)</td><td align="left" valign="bottom">Invivogen</td><td align="left" valign="bottom">tlrl-b5lps</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Aldara (Imiquimod)</td><td align="left" valign="bottom">Meda Pharmaceuticals</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">5% cream</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Anakinra</td><td align="left" valign="bottom">Swedish Orphan Biovitrum</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">150 mg/ml</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Etanercept (Enbrel)</td><td align="left" valign="bottom">Pfizer Europe</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">25 mg</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Baytril</td><td align="left" valign="bottom">Bayer Corporation</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tamoxifen</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat# T5648-1G</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phorbol 12-myristate 13-acetate (TPA)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# P8139</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tetramethylrhodamine isothiocyanate–Dextran, 70 kDa</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# T11-62</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Bromodeoxyuridine (BrDU)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat# 423401</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Liberase TM Research grade</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat# 5401119001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DNase I (grade II) from bovine pancreas</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 10104159001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNA-Later</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# AM7020</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">LIVE/DEAD Fixable Aqua Dead Cell Stain Kit</td><td align="left" valign="bottom">Life Technologies</td><td align="left" valign="bottom">Cat# L34597</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">BD FACS Lysis Solution 10X Concentrate</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 349202</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNEasy Mini Kit</td><td align="left" valign="bottom">QIAGEN</td><td align="left" valign="bottom">Cat# 74104</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNEasy Micro Plus Kit</td><td align="left" valign="bottom">QIAGEN</td><td align="left" valign="bottom">Cat# 74034</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">iScript cDNA Synthesis Kit</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">Cat# 1708891</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">QuantiTect Probe PCR Kit</td><td align="left" valign="bottom">QIAGEN</td><td align="left" valign="bottom">Cat# 204343</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">High-Capacity RNA-to-cDNA kit</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">Cat# 4387406</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Legendplex Mix and Match Kit</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">BrdU Staining Kit</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 8817-6600</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus,</italic> C57BL/6)</td><td align="left" valign="bottom">B6.129P-Cx3cr1<sup>tm1Litt</sup>/J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">JAX stock #005582</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib38">Jung et al., 2000</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus,</italic> C57BL/6)</td><td align="left" valign="bottom">B6(Cg)-Ifnar1tm1.2Ees/J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">JAX stock #028288</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib35">Hwang et al., 1995</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus,</italic> C57BL/6)</td><td align="left" valign="bottom">B6(Cg)-Rag2<sup>tm1.1Cgn</sup>/J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">JAX stock #08449</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib32">Hao and Rajewsky, 2001</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus,</italic> C57BL/6)</td><td align="left" valign="bottom">B6.129P2-Lyz2<sup>tm1(cre)Ifo</sup>/J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">JAX stock #004781</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib14">Clausen et al., 1999</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus,</italic> C57BL/6)</td><td align="left" valign="bottom">B6.129(Cg)-Ccr2<sup>tm2.1Ifc</sup>/J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">JAX stock #017586</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib57">Saederup et al., 2010</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus,</italic> C57BL/6)</td><td align="left" valign="bottom">B6.129P2-Tlr7<sup>tm1Aki</sup></td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib33">Hemmi et al., 2002</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus,</italic> C57BL/6)</td><td align="left" valign="bottom">B6.129S7-Ifng<sup>tm1Ts</sup>/J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">JAX stock #002287</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib19">Dalton et al., 1993</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus;</italic> C57BL/6)</td><td align="left" valign="bottom">Tlr7<sup>flox/flox</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib66">Solmaz et al., 2019</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus;</italic> BALB/c)</td><td align="left" valign="bottom">Cpa3- cre<sup>4Glli</sup></td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">JAX stock #026828</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib23">Feyerabend et al., 2011</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus;</italic> BALB/c)</td><td align="left" valign="bottom">Gata1<sup>tm6Sho</sup>/J</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">JAX stock #05653</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib81">Yu et al., 2002</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>M. musculus;</italic> C57BL/6)</td><td align="left" valign="bottom">HSC-SCL-Cre-ER<sup>T</sup>;R26R-EYFP</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib28">Göthert et al., 2005</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background<break/>(influenza A virus)</td><td align="left" valign="bottom">strain X31</td><td align="left" valign="bottom">John McCauley</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Davidson, S.,<break/>2014</td></tr><tr><td align="left" valign="bottom">Strain, strain background (RSV)</td><td align="left" valign="bottom">Strain A2</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">ATCC VR-1540</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">RSV L gene forward</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">GAACTCAGT GTA GGT</named-content> <named-content content-type="sequence">AGAATGTTTGCA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">RSV L gene reverse</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">TTCAGCTATCATTTTCTCTGCCAAT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">RSV L FAM-TAMRA probe</td><td align="left" valign="bottom">Eurofins MWG Operon</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">TTTGAACCTGTCTGAACATTCCCGGTT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Flu M1 gene forward</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">AAGACCAATCCTGTCACCTCTGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"> Flu M1 gene reverse</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">CAAAGCGTCTACGCTGCA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Flu M1 FAM-TAMRA probe</td><td align="left" valign="bottom">Eurofins MWG Operon</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><named-content content-type="sequence">TTTGTGTTCACGCTCACCGT</named-content></td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Software (Prism)</td><td align="left" valign="bottom">GraphPad Software, Inc, La Jolla, California, USA</td><td align="left" valign="bottom">Version 9</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom">Tree Star Inc Ashland, OR, USA</td><td align="left" valign="bottom">Version 10.7.1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Imaris 8.0.1</td><td align="left" valign="bottom">Bitplane AG</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FIJI</td><td align="left" valign="bottom">ImageJ2 (open source)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">7500 Fast System SDS v1.4 21 CFR Part 11 Module</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">QuantStudio Software V1.2.4</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Mouse strains</title><p>All procedures were carried out in accordance with the institutional guidelines and the studies were approved by the UK Home Office. Experimental studies were designed according to the ARRIVE guidelines (<xref ref-type="bibr" rid="bib54">Percie du Sert et al., 2020</xref>). Experimental mice were 8–12 wk of age, sex-, and age-matched. All animals were housed in individually ventilated cages. The animals were selected randomly from a large pool, but no specific method of randomisation was used to allocate mice into groups. The investigators were not blinded to allocation during experiment and outcome assessment.</p><p>BALB/c and C57BL/6 mice were purchased from Charles River (UK). The following mice were as previously described and maintained on a C57BL/6 background: B6.129P-<italic>Cx3cr1</italic><sup>tm1Litt/J</sup>(<italic>Cx<sub>3</sub>cr1<sup>GFP/GFP</sup></italic>) (<xref ref-type="bibr" rid="bib38">Jung et al., 2000</xref>), <italic>Ifnar1<sup>-/-</sup></italic> (<xref ref-type="bibr" rid="bib35">Hwang et al., 1995</xref>), B6(Cg)-Rag2<sup>tm1.1Cgn</sup>/J (<italic>Rag2<sup>-/-</sup></italic>) (<xref ref-type="bibr" rid="bib32">Hao and Rajewsky, 2001</xref>), B6.129P2-Lyz2<sup>tm1(cre)Ifo</sup>/J (<italic>Lyz2<sup>Cre</sup></italic>) (<xref ref-type="bibr" rid="bib14">Clausen et al., 1999</xref>), B6.129(Cg)-Ccr2<sup>tm2.1Ifc</sup>/J (<italic>Ccr2<sup>RFP/RFP</sup></italic>) (<xref ref-type="bibr" rid="bib57">Saederup et al., 2010</xref>), B6.129P2-Tlr7<sup>tm1Aki</sup> (<italic>Tlr7<sup>-/-</sup></italic>) (<xref ref-type="bibr" rid="bib33">Hemmi et al., 2002</xref>), B6.129S7-<sup>Ifngtm1Ts</sup>/J (<italic>Ifng<sup>-/-</sup></italic>) (<xref ref-type="bibr" rid="bib19">Dalton et al., 1993</xref>), <italic>Tlr7<sup>fl</sup></italic> (<xref ref-type="bibr" rid="bib66">Solmaz et al., 2019</xref>), and HSC-SCL-Cre-ER<sup>T</sup>;R26R-EYFP (<xref ref-type="bibr" rid="bib28">Göthert et al., 2005</xref>). The following mice were as previously described and maintained on a BALB/c background: <italic>Gata1<sup>tm6Sho</sup></italic>/J (ΔdblGATA) (<xref ref-type="bibr" rid="bib81">Yu et al., 2002</xref>), <italic>Cpa3<sup>Cre/+</sup></italic> (<xref ref-type="bibr" rid="bib23">Feyerabend et al., 2011</xref>).</p></sec><sec id="s4-2"><title>In vivo administration of TLR agonists</title><sec id="s4-2-1"><title>Topical application</title><p>Mice were treated on the dorsal side of the right ear with 100 µg of R848 (Enzo Life Sciences, USA) diluted in 30 µl of acetone, three times per week up to a maximum of 12 treatments. The same dosing regimen was used for the following TLR ligands: lipopolysaccharide (LPS) from <italic>Escherichia coli</italic> 055:B5 (Invivogen), low molecular weight polyinosine-polycytidylic acid (Poly(I:C), Invivogen), Class C CpG oligonucleotide ODN-2395 (Invivogen). They were dissolved in 50:50 DMSO:PBS and applied topically at 100 µg per dose. Imiquimod (IMQ) at a dose of 5 mg of 5% IMQ cream (Aldara cream, 3M Pharmaceutical) was applied on the ventral side of one ear for five consecutive days. 5 nmol of 12-O-tetradecanoylphorbol-13-acetate (TPA) dissolved in ethanol was applied topically on the dorsal ear skin four times over 2 wk.</p></sec><sec id="s4-2-2"><title>Other routes of administration</title><p>(i) Mice treated intraperitoneally IP received 100 µg of a water-soluble R848 formulation (Invivogen) dissolved in 200 µl of PBS, three times per week; (ii) mice treated intravenously received 100 µg of water-soluble R848 in 100 µl of PBS, three times per week. Vehicle-treated mice were used as controls; (iii) mice treated orally received drinking water supplemented with R848 (Invivogen) at 6.3 µg/ml to provide a calculated dose of ~50 µg/day/mouse. Sodium saccharine sweetener (Sweetex) was added at two tablets per 100 ml to improve palatability. Monocyte counts were monitored by flow cytometry of the peripheral blood at the indicated time points, as described in blood sampling.</p></sec></sec><sec id="s4-3"><title>Blocking and depletion experiments</title><sec id="s4-3-1"><title>Blocking antibody</title><p>Mice were injected IP with 10 mg of the anti-IL1R Anakinra (Kineret, Sobi, Sweden) for seven consecutive days, starting on the day of the first R848 treatment. Mice simultaneously received topical treatments every other day with either R848 or acetone. Mice were injected IP with 200 mg of the anti-TNF Etanercept (Enbrel) or PBS for nine consecutive days, starting 2 d prior to the first R848 treatment. Mice were injected IP with 200 mg of the anti-IL-6R (Clone 15A7, BioXcell) or isotype control (BioXcell) or PBS every 3 d, starting 1 d prior to the first R848 treatment. Mice then received topical R848 treatments every other day for four times. Monocyte counts were assessed by flow cytometry at the indicated time points, as described in blood sampling.</p></sec><sec id="s4-3-2"><title>Neutrophil depletion</title><p>Mice were injected IP with 200 µg of a chimeric anti-Ly6G antibody composed of the 1A8 variable region with a mouse IgG2a Fc region to avoid eliciting a neutralising response (Absolute Antibody) (<xref ref-type="bibr" rid="bib18">Daley et al., 2008</xref>). Mice received four topical R848 treatments at a frequency of three treatments per week and antibody was injected 4 hr prior to each R848 treatment. Blood neutrophil depletion was validated by flow cytometry, with neutrophils defined independently of their Ly6G expression as SSC<sup>high</sup>, CD11b<sup>pos</sup>, Ly6C<sup>int</sup>, CD115<sup>neg</sup>.</p></sec><sec id="s4-3-3"><title>Ly6C-high monocyte depletion</title><p>Mice were injected IP with 100 µg of a chimeric anti-GR1 antibody composed of the RB6-8C5 variable region with a mouse IgG2a Fc region to avoid eliciting a neutralising response (Absolute Antibody). Mice received four topical R848 treatments at a frequency of three treatments per week and antibody was injected on three consecutive days, starting with the third R848 treatment. Blood monocyte depletion was validated by flow cytometry at 24 hr after each antibody injection.</p></sec></sec><sec id="s4-4"><title>Splenectomy</title><p>Eight-week-old BALB/c mice underwent surgical splenectomy or sham surgery under aseptic conditions. Briefly, mice were injected subcutaneously with ketamine (80 mg/kg) and xylazine (16 mg/kg) before being anaesthetised with 5% isofluorane. Mice were rested for 6 wk before being treated six times with 100 µg topical R848 over 2 wk. To assess monocytosis, a blood sample was taken prior to the first R848 treatment and at 24 hr after each treatment.</p></sec><sec id="s4-5"><title>Intravital microscopy</title><p><italic>Cx<sub>3</sub>cr1</italic><sup>GFP/+</sup> mice, 10–12 wk of age, were treated topically for four times with R848 or acetone on one ear, before being used for imaging. Intravital imaging of the dermis of the contralateral ear was performed as previously described (<xref ref-type="bibr" rid="bib12">Carlin et al., 2013</xref>). Briefly, after IP administration of anaesthetic cocktail of fentanyl/fluanisone and midazolam, mice were maintained at 37°C with oxygen supplementation. 80 μl of tetramethylrhodamine (TRITC) conjugated 70 kDa dextran (70 μM) was injected IV and the ear to be imaged was taped to the centre of the coverslip. Light was generated from 488 nm and 562 nm lasers, emitted light signal was detected to generate two colour 8-bit images using a ×10/0.4 objective on a Leica SP5 confocal microscope. Images were analysed using Imaris software (Bitplane). Dextran signal was used to identify the intravascular cells and monocytes were automatically selected on the base of the quality and intensity of their GFP signal.</p></sec><sec id="s4-6"><title>BrDU incorporation</title><p>C57BL/6 mice were treated twice with topical R848 and then were injected once IP with 2 mg of (5-bromo-2’-deoxyuridine) BrdU (BioLegend). BM was harvested 16 hr later and samples were processed with BrdU staining kit (eBioscience, USA) according to the manufacturer’s provided protocol and analysed by flow cytometry (see details in ‘Materials and methods’).</p></sec><sec id="s4-7"><title>Lineage tracing experiment</title><p>HSC-SCL-Cre-ER<sup>T</sup>;R26R-EYFP mice were given 100 μl tamoxifen (40 mg/ml) by oral gavage for five consecutive days. After 3 d, some mice received topical R848 treatments every other day for four times and others were left untreated. Monocyte counts were assessed by flow cytometry at the indicated time points, as described in blood sampling.</p></sec><sec id="s4-8"><title>Bone marrow chimeras</title><p>Prior to irradiation, all mice were treated orally with Baytril (Bayer) for 7 d and moved to sterile cages. C57BL/6 or <italic>Tlr7<sup>-/-</sup></italic> host mice were lethally irradiated (700 cGy) and reconstituted IV on the same day with 5 × 10<sup>6</sup> BM cells from either C57BL/6 or <italic>Tlr7<sup>-/-</sup></italic> donor mice. Mice were left to recover for 8 wk and reconstitution was confirmed by blood sampling and flow cytometry. Reconstituted mice were treated topically with 100 µg R848, three times per week for four treatments.</p></sec><sec id="s4-9"><title>Vascular permeability</title><p>BALB/c mice were naive or treated topically four times with 100 µg R848. 200 µl of 0.5% Evans Blue in PBS was injected IV at 24 hr after the final R848 treatment. Mice were culled by cervical dislocation after 30 min, and ears and right tibia were harvested. Ears were minced into a slurry and tibias were crushed, before adding each to 500 µl formamide. After 48 hr of incubation at room temperature, the absorbance of the formamide was read at 620 nm and concentration of Evans Blue was calculated using a standard curve.</p></sec><sec id="s4-10"><title>Virus infections and qPCR</title><p>C57BL/6 were naive or treated topically five times with 100 µg R848 prior to infection with the influenza A virus strain X31 (obtained from John McCauley, The Francis Crick Institute, UK) or plaque-purified human RSV (originally A2 strain from ATCC, USA, grown in HEp2 cells). The topical application of R848 was continued during the viral infection. For infections, mice were lightly anaesthetised (3% isofluorane) and virus was intranasally (IN) administered. Mice received 8 × 10<sup>5</sup> focus-forming units (FFU) of RSV or 250 plaque-forming units (PFU) of X31, both given in 100 µl. Weight was monitored daily. Mice were sacrificed at day 7 (X31) and day 4 (RSV) post infection (p.i.) and lung lobes were stored in RNA-later (Sigma). Lung tissue was homogenised using a TissueLyser LT (QIAGEN), and total RNA was extracted using RNeasy Mini kit including DNA removal (QIAGEN) according to the manufacturer’s instructions. 1–2 µg of RNA was reverse-transcribed using the High-Capacity RNA-to-cDNA kit according to the manufacturer’s instructions (Applied Biosystems). qPCR was performed to quantify lung RNA levels using the mastermix QuantiTech Probe PCR kit (QIAGEN). To quantify RSV L genes, primers and FAM-TAMRA probes previously described were used (<xref ref-type="bibr" rid="bib44">Lee et al., 2010</xref>). The absolute number of gene copies was calculated using a plasmid DNA standard curve and the results were normalised to levels of <italic>Gapdh</italic> (Applied Biosystems). The relative quantification of X31 M genes (primers from <xref ref-type="bibr" rid="bib75">Ward et al., 2004</xref>) was expressed relatively to the expression of <italic>Gapdh</italic>. First, the ΔCt (Ct = cycle threshold) between the target gene and the <italic>Gapdh</italic> for each sample was calculated, then the expression was calculated as 2<sup>-ΔCt</sup>. Analysis was performed using 7500 Fast System SDS software (Applied Biosystems).</p></sec><sec id="s4-11"><title>In vitro stimulation</title><p>C57BL/6 mice were naïve or treated topically four times with 100 µg R848. Femur and tibia were harvested without breaking the bone, to maintain sterility. Collected bones were placed into RPMI 1640 (Gibco), 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin. Bones were cleaned and flushed with HBSS- 2% FCS and cells were pooled from two mice per biological replicate. Cell suspensions were washed and re-suspended in hypotonic red blood cell lysis buffer (RBC Lysis Buffer: 1 l of water, 8.02 g NH<sub>4</sub>Cl, 0.84 g NaHCO<sub>3</sub>, 0.37 g EDTA) for 5 min on ice. Cells were wash and resuspended in PBS solution containing 1% BSA, 2 mM EDTA (Sorting buffer), and cell surface staining was then performed using the fluorochrome-conjugated antibodies as in ‘Flow cytometry<bold>’</bold>. Monocytes were sorted into HBSS- 2% FCS in 15 ml Falcon tubes using a BD Aria III (BD Biosciences). Monocytes were gated as Lineage-negative (B220, CD49b, Ly6G), CD115-positive, CD117-negative, and CD11b-positive. Sorted cells were washed and resuspended in DMEM (Gibco), 20% FCS, 100 U/ml penicillin, and 100 g/ml streptomycin, 2 mM L-glutamine at 1 × 10<sup>6</sup> per ml. 1 × 10<sup>5</sup> cells per replicate were stimulated with either 100 ng/ml R848 (Invivogen) or 1 µg/ml LPS (O127:B8, Sigma) or medium alone for 16 hr. Supernatant was harvested and cytokines were quantified using a Legendplex Mix and Match Kit according to the manufacturer’s instructions (BioLegend).</p></sec><sec id="s4-12"><title>Method details</title><sec id="s4-12-1"><title>Flow cytometry</title><p>Where live/dead staining was performed, single-cell suspensions were stained for 20 min at room temperature with Live/Dead Fixable Dead Cell Stain (Life) at the dilution of 1/1000 in PBS, as per the manufacturer’s protocol. Cells were incubated with a saturating concentration of 2.4G2 monoclonal antibody (anti-CD16/32) to block non-specific Fc receptor binding and stained in PBS solution containing 1% BSA, 2 mM EDTA, and 0.09% NaN<sub>3</sub> (FACS buffer) with an appropriate dilution of fluorophore-conjugated antibodies for 20 min at 4°C (see antibodies used in the Key Resources Table). Samples were acquired on either a Fortessa X20 (BD Biosciences) or an Aurora (Cytek) flow cytometer and analysed using FlowJo X for Mac (TreeStar).</p></sec><sec id="s4-12-2"><title>Blood sampling</title><p>Tail vein blood samples were added to an equal volume of 100 mM EDTA, washed, and resuspended in FACS buffer. Cell surface staining was then performed using the fluorochrome-conjugated antibodies listed in ‘Flow cytometry’. After antibody staining, cells were washed and red blood cells were removed by hypotonic lysis using BD FACS Lysing Solution (BD Biosciences). Absolute cell counts were quantified with AccuCheck counting beads (Thermo Fisher Scientific, USA) as per the manufacturer’s protocol. Total blood monocytes were gated as follows and as illustrated in <xref ref-type="fig" rid="fig1">Figure 1C</xref>: CD3-neg, B220-neg, CD11b+, CD115+. Monocytes were then split into Ly6C-high and Ly6C-low subpopulations based on their expression of Ly6C and CD11a.</p></sec><sec id="s4-12-3"><title>Bone marrow staining</title><p>Femur and tibia were harvested without breaking the bone to avoid blood contamination. Collected bones were placed into RPMI 1640 (Gibco), 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin. Bones were cleaned and flushed with HBSS- 2% FCS, and cell suspensions were washed and resuspended in hypotonic BD FACS Lysing Solution (BD Biosciences) for 2 min on ice. Cells were washed and resuspended in FACS buffer. Antibody staining was performed as described above in ‘Flow cytometry’. The gating for BM populations was adapted from a published strategy (<xref ref-type="bibr" rid="bib79">Yáñez et al., 2017</xref>) and is illustrated in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>. All populations are first gated lineage-negative (CD3, B220, Ly6G, CD49b). Haematopoietic stem and progenitor cells, HSPC: CD115-neg, c-kit+, Sca-1-neg; monocyte-dendritic cell progenitor, MDP: CD115+, c-Kit+, Ly6C-low; common monocyte progenitor, cMoP: CD115+, c-Kit+, Ly6C-high, Flt3-neg; granulocyte-monocyte progenitor, GMP: CD115-neg, cKit+, Sca-1-neg, CD16/32 + , Ly6C-low; common myeloid progenitor, CMP: CD115-neg, cKit+, Sca-1-neg, CD16/32-neg, Ly6C-low; granulocyte-committed progenitor, GP: CD115-neg, cKit+, Sca-1-neg, CD16/32+, Ly6C-high; Ly6C-high monocytes: CD115+, c-Kit-neg, Ly6C-high; Ly6C-low monocytes: CD115+, c-Kit-neg, Ly6C-low.</p></sec><sec id="s4-12-4"><title>Skin digestion</title><p>Single-cell suspensions from ear skin was obtained as follows: (i) ears were split dorsal-ventral using forceps to analyse only the dorsal (treated) side; (ii) skin was cut into ~1 mm<sup>2</sup> pieces using a scalpel blade and incubated for 2 hr in digestion buffer containing 25 μg/ml Liberase (Roche), 250 μg/ml DNAseI (Roche), and 1 × DNAse buffer (1.21 Tris base, 0.5  g MgCl<sub>2</sub> and 0.073  g CaCl<sub>2</sub>) at 37°C; (iii) pieces were transferred into C-tubes (Miltenyi Biotech) containing RPMI-1640 medium (Thermo Fisher) supplemented with 10% heat-inactivated FCS and physically disrupted using a GentleMACS dissociator (Miltenyi); (iv) cell suspensions were then filtered through 70 µM cell strainers (BD Biosciences) and counted using a CASY cell counter (Roche). Cell suspensions were stained as described above in ‘Flow cytometry’.</p></sec><sec id="s4-12-5"><title>Immunohistochemistry</title><p>Lungs, livers, and kidneys were harvested and snap frozen in OCT using isopentane cooled to –80°C on dry ice. 9 µM sections were cut using a Leica JUNG CM1800 cryostat and stored at –80°C. For staining, slides were equilibrated to room temperature before fixation in ice-cold acetone for 10 min. Sections were blocked in PBS with 5% BSA and 10% serum (dependent on the species of the secondary antibody being used) for 1 hr at room temperature. All antibody staining steps were performed in PBS 5% BSA 0.1% Triton X-100 for 45 min at room temperature. The following primary antibodies were used: anti-CD68 Alexa Fluor 488 (FA-11, BioLegend), anti-F4/80 Alexa Fluor 488 (BM8), anti-CD43 (S11, BioLegend). Hoechst 33342 (NucBlue, Thermo Fisher) was added to the final staining step according to the manufacturer’s instructions and sections were mounted in ProLong Glass (Thermo Fisher). Images were acquired on a Zeiss Axio Observer inverted widefield microscope using a Colibri.2 LED illumination source, a ×20/0.8 plan-apochromat objective and a Hamamatsu Flash 4.0 camera. Images were processed to correct brightness and contrast in FIJI (<xref ref-type="bibr" rid="bib59">Schindelin et al., 2012</xref>). Cell quantification was performed using the surfaces function of Imaris 8 (Bitplane), with a minimum of five randomly selected fields per section being used for analysis. Data are expressed as the mean number of cells per field.</p></sec></sec><sec id="s4-13"><title>Quantification and statistical analysis</title><p>Statistical comparisons between two groups at a single time point were performed using a two-tailed, unpaired <italic>t</italic>-test. In experiments with more than two groups at a single time point, analysis was by one-way ANOVA with Tukey’s multiple-comparison test. For data sets with multiple groups over a time course, analysis was performed using two-way ANOVA with either Tukey’s or Bonferroni’s multiple-comparison test as appropriate and indicated in the figure legends. Statistical analysis was performed using Prism 9.0 (GraphPad).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Resources, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Supervision</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Supervision, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All procedures were carried out in accordance with the institutional guidelines and the studies were approved by the UK Home Office. Experimental studies were designed according the ARRIVE guidelines.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-85647-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Tim Sparwasser for providing the <italic>Tlr7</italic>-floxed mice. We are indebted to the staff of the Imperial Central Biomedical Services for the care of the animals and the LMS/NIHR Imperial Biomedical Research Centre Flow Cytometry Facility for FACS support. CG was supported by an award from Imperial Institutional Strategic Support Fund. The research reported herein was supported by the Wellcome Trust (grant reference number: 108008/Z/15/Z [to MB] and 102126/B/13/Z [to CJ:AO]). CG was supported by an Imperial Wellcome Trust Institutional Strategic Support Fund and TCL by a Sir Henry Dale Fellowship from the Wellcome Trust and Royal Society (210424/Z/18/Z) and a KKLF project grant (KKL1379). We acknowledge contribution from the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abidin</surname><given-names>BM</given-names></name><name><surname>Hammami</surname><given-names>A</given-names></name><name><surname>Stäger</surname><given-names>S</given-names></name><name><surname>Heinonen</surname><given-names>KM</given-names></name><name><surname>Engwerda</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Infection-adapted emergency hematopoiesis promotes visceral leishmaniasis</article-title><source>PLOS Pathogens</source><volume>13</volume><elocation-id>e1006422</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006422</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abram</surname><given-names>CL</given-names></name><name><surname>Roberge</surname><given-names>GL</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Lowell</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Comparative analysis of the efficiency and specificity of myeloid-Cre deleting strains using ROSA-EYFP reporter mice</article-title><source>Journal of Immunological Methods</source><volume>408</volume><fpage>89</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2014.05.009</pub-id><pub-id pub-id-type="pmid">24857755</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akilesh</surname><given-names>HM</given-names></name><name><surname>Buechler</surname><given-names>MB</given-names></name><name><surname>Duggan</surname><given-names>JM</given-names></name><name><surname>Hahn</surname><given-names>WO</given-names></name><name><surname>Matta</surname><given-names>B</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Gessay</surname><given-names>G</given-names></name><name><surname>Whalen</surname><given-names>E</given-names></name><name><surname>Mason</surname><given-names>M</given-names></name><name><surname>Presnell</surname><given-names>SR</given-names></name><name><surname>Elkon</surname><given-names>KB</given-names></name><name><surname>Lacy-Hulbert</surname><given-names>A</given-names></name><name><surname>Barnes</surname><given-names>BJ</given-names></name><name><surname>Pepper</surname><given-names>M</given-names></name><name><surname>Hamerman</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Chronic TLR7 and TLR9 signaling drives anemia via differentiation of specialized hemophagocytes</article-title><source>Science</source><volume>363</volume><elocation-id>eaao5213</elocation-id><pub-id pub-id-type="doi">10.1126/science.aao5213</pub-id><pub-id pub-id-type="pmid">30630901</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Askenase</surname><given-names>MH</given-names></name><name><surname>Han</surname><given-names>S-J</given-names></name><name><surname>Byrd</surname><given-names>AL</given-names></name><name><surname>Morais da Fonseca</surname><given-names>D</given-names></name><name><surname>Bouladoux</surname><given-names>N</given-names></name><name><surname>Wilhelm</surname><given-names>C</given-names></name><name><surname>Konkel</surname><given-names>JE</given-names></name><name><surname>Hand</surname><given-names>TW</given-names></name><name><surname>Lacerda-Queiroz</surname><given-names>N</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Trinchieri</surname><given-names>G</given-names></name><name><surname>Grainger</surname><given-names>JR</given-names></name><name><surname>Belkaid</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Bone-marrow-resident nk cells prime monocytes for regulatory function during infection</article-title><source>Immunity</source><volume>42</volume><fpage>1130</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.05.011</pub-id><pub-id pub-id-type="pmid">26070484</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auffray</surname><given-names>C</given-names></name><name><surname>Fogg</surname><given-names>D</given-names></name><name><surname>Garfa</surname><given-names>M</given-names></name><name><surname>Elain</surname><given-names>G</given-names></name><name><surname>Join-Lambert</surname><given-names>O</given-names></name><name><surname>Kayal</surname><given-names>S</given-names></name><name><surname>Sarnacki</surname><given-names>S</given-names></name><name><surname>Cumano</surname><given-names>A</given-names></name><name><surname>Lauvau</surname><given-names>G</given-names></name><name><surname>Geissmann</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior</article-title><source>Science</source><volume>317</volume><fpage>666</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1126/science.1142883</pub-id><pub-id pub-id-type="pmid">17673663</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bachmanov</surname><given-names>AA</given-names></name><name><surname>Reed</surname><given-names>DR</given-names></name><name><surname>Beauchamp</surname><given-names>GK</given-names></name><name><surname>Tordoff</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Food intake, water intake, and drinking spout side preference of 28 mouse strains</article-title><source>Behavior Genetics</source><volume>32</volume><fpage>435</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1023/A:1020884312053</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bain</surname><given-names>CC</given-names></name><name><surname>Bravo-Blas</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>CL</given-names></name><name><surname>Perdiguero</surname><given-names>EG</given-names></name><name><surname>Geissmann</surname><given-names>F</given-names></name><name><surname>Henri</surname><given-names>S</given-names></name><name><surname>Malissen</surname><given-names>B</given-names></name><name><surname>Osborne</surname><given-names>LC</given-names></name><name><surname>Artis</surname><given-names>D</given-names></name><name><surname>Mowat</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice</article-title><source>Nature Immunology</source><volume>15</volume><fpage>929</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1038/ni.2967</pub-id><pub-id pub-id-type="pmid">25151491</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldridge</surname><given-names>MT</given-names></name><name><surname>King</surname><given-names>KY</given-names></name><name><surname>Boles</surname><given-names>NC</given-names></name><name><surname>Weksberg</surname><given-names>DC</given-names></name><name><surname>Goodell</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection</article-title><source>Nature</source><volume>465</volume><fpage>793</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1038/nature09135</pub-id><pub-id pub-id-type="pmid">20535209</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>SK</given-names></name><name><surname>Lopez-Collazo</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Endotoxin tolerance: new mechanisms, molecules and clinical significance</article-title><source>Trends in Immunology</source><volume>30</volume><fpage>475</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/j.it.2009.07.009</pub-id><pub-id pub-id-type="pmid">19781994</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryden</surname><given-names>SR</given-names></name><name><surname>Pingen</surname><given-names>M</given-names></name><name><surname>Lefteri</surname><given-names>DA</given-names></name><name><surname>Miltenburg</surname><given-names>J</given-names></name><name><surname>Delang</surname><given-names>L</given-names></name><name><surname>Jacobs</surname><given-names>S</given-names></name><name><surname>Abdelnabi</surname><given-names>R</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name><name><surname>Pondeville</surname><given-names>E</given-names></name><name><surname>Major</surname><given-names>J</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name><name><surname>Khalid</surname><given-names>H</given-names></name><name><surname>Tuplin</surname><given-names>A</given-names></name><name><surname>Varjak</surname><given-names>M</given-names></name><name><surname>Merits</surname><given-names>A</given-names></name><name><surname>Edgar</surname><given-names>J</given-names></name><name><surname>Graham</surname><given-names>GJ</given-names></name><name><surname>Shams</surname><given-names>K</given-names></name><name><surname>McKimmie</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pan-viral protection against arboviruses by activating skin macrophages at the inoculation site</article-title><source>Science Translational Medicine</source><volume>12</volume><elocation-id>eaax2421</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aax2421</pub-id><pub-id pub-id-type="pmid">31969486</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buechler</surname><given-names>MB</given-names></name><name><surname>Teal</surname><given-names>TH</given-names></name><name><surname>Elkon</surname><given-names>KB</given-names></name><name><surname>Hamerman</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Cutting Edge: Type I IFN Drives emergency myelopoiesis and peripheral myeloid expansion during chronic TLR7 signaling</article-title><source>The Journal of Immunology</source><volume>190</volume><fpage>886</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202739</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlin</surname><given-names>LM</given-names></name><name><surname>Stamatiades</surname><given-names>EG</given-names></name><name><surname>Auffray</surname><given-names>C</given-names></name><name><surname>Hanna</surname><given-names>RN</given-names></name><name><surname>Glover</surname><given-names>L</given-names></name><name><surname>Vizcay-Barrena</surname><given-names>G</given-names></name><name><surname>Hedrick</surname><given-names>CC</given-names></name><name><surname>Cook</surname><given-names>HT</given-names></name><name><surname>Diebold</surname><given-names>S</given-names></name><name><surname>Geissmann</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal</article-title><source>Cell</source><volume>153</volume><fpage>362</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.03.010</pub-id><pub-id pub-id-type="pmid">23582326</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>SZ</given-names></name><name><surname>Evrard</surname><given-names>M</given-names></name><name><surname>Devi</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>JY</given-names></name><name><surname>See</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Adrover</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>JLY</given-names></name><name><surname>Liong</surname><given-names>KH</given-names></name><name><surname>Phua</surname><given-names>C</given-names></name><name><surname>Balachander</surname><given-names>A</given-names></name><name><surname>Boey</surname><given-names>A</given-names></name><name><surname>Liebl</surname><given-names>D</given-names></name><name><surname>Tan</surname><given-names>SM</given-names></name><name><surname>Chan</surname><given-names>JKY</given-names></name><name><surname>Balabanian</surname><given-names>K</given-names></name><name><surname>Harris</surname><given-names>JE</given-names></name><name><surname>Bianchini</surname><given-names>M</given-names></name><name><surname>Weber</surname><given-names>C</given-names></name><name><surname>Duchene</surname><given-names>J</given-names></name><name><surname>Lum</surname><given-names>J</given-names></name><name><surname>Poidinger</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Rénia</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>C-I</given-names></name><name><surname>Larbi</surname><given-names>A</given-names></name><name><surname>Randolph</surname><given-names>GJ</given-names></name><name><surname>Weninger</surname><given-names>W</given-names></name><name><surname>Looney</surname><given-names>MR</given-names></name><name><surname>Krummel</surname><given-names>MF</given-names></name><name><surname>Biswas</surname><given-names>SK</given-names></name><name><surname>Ginhoux</surname><given-names>F</given-names></name><name><surname>Hidalgo</surname><given-names>A</given-names></name><name><surname>Bachelerie</surname><given-names>F</given-names></name><name><surname>Ng</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CXCR4 identifies transitional bone marrow premonocytes that replenish the mature monocyte pool for peripheral responses</article-title><source>The Journal of Experimental Medicine</source><volume>213</volume><fpage>2293</fpage><lpage>2314</lpage><pub-id pub-id-type="doi">10.1084/jem.20160800</pub-id><pub-id pub-id-type="pmid">27811056</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clausen</surname><given-names>BE</given-names></name><name><surname>Burkhardt</surname><given-names>C</given-names></name><name><surname>Reith</surname><given-names>W</given-names></name><name><surname>Renkawitz</surname><given-names>R</given-names></name><name><surname>Förster</surname><given-names>I</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Conditional gene targeting in macrophages and granulocytes using LysMcre mice</article-title><source>Transgenic Research</source><volume>8</volume><fpage>265</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1023/a:1008942828960</pub-id><pub-id pub-id-type="pmid">10621974</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrady</surname><given-names>CD</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Mandal</surname><given-names>NA</given-names></name><name><surname>van Rooijen</surname><given-names>N</given-names></name><name><surname>Carr</surname><given-names>DJJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>IFN-α-driven CCL2 production recruits inflammatory monocytes to infection site in mice</article-title><source>Mucosal Immunology</source><volume>6</volume><fpage>45</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/mi.2012.46</pub-id><pub-id pub-id-type="pmid">22692455</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortez-Retamozo</surname><given-names>V</given-names></name><name><surname>Etzrodt</surname><given-names>M</given-names></name><name><surname>Newton</surname><given-names>A</given-names></name><name><surname>Rauch</surname><given-names>PJ</given-names></name><name><surname>Chudnovskiy</surname><given-names>A</given-names></name><name><surname>Berger</surname><given-names>C</given-names></name><name><surname>Ryan</surname><given-names>RJH</given-names></name><name><surname>Iwamoto</surname><given-names>Y</given-names></name><name><surname>Marinelli</surname><given-names>B</given-names></name><name><surname>Gorbatov</surname><given-names>R</given-names></name><name><surname>Forghani</surname><given-names>R</given-names></name><name><surname>Novobrantseva</surname><given-names>TI</given-names></name><name><surname>Koteliansky</surname><given-names>V</given-names></name><name><surname>Figueiredo</surname><given-names>J-L</given-names></name><name><surname>Chen</surname><given-names>JW</given-names></name><name><surname>Anderson</surname><given-names>DG</given-names></name><name><surname>Nahrendorf</surname><given-names>M</given-names></name><name><surname>Swirski</surname><given-names>FK</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Pittet</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Origins of tumor-associated macrophages and neutrophils</article-title><source>PNAS</source><volume>109</volume><fpage>2491</fpage><lpage>2496</lpage><pub-id pub-id-type="doi">10.1073/pnas.1113744109</pub-id><pub-id pub-id-type="pmid">22308361</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cros</surname><given-names>J</given-names></name><name><surname>Cagnard</surname><given-names>N</given-names></name><name><surname>Woollard</surname><given-names>K</given-names></name><name><surname>Patey</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>S-Y</given-names></name><name><surname>Senechal</surname><given-names>B</given-names></name><name><surname>Puel</surname><given-names>A</given-names></name><name><surname>Biswas</surname><given-names>SK</given-names></name><name><surname>Moshous</surname><given-names>D</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Jais</surname><given-names>J-P</given-names></name><name><surname>D’Cruz</surname><given-names>D</given-names></name><name><surname>Casanova</surname><given-names>J-L</given-names></name><name><surname>Trouillet</surname><given-names>C</given-names></name><name><surname>Geissmann</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors</article-title><source>Immunity</source><volume>33</volume><fpage>375</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.08.012</pub-id><pub-id pub-id-type="pmid">20832340</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daley</surname><given-names>JM</given-names></name><name><surname>Thomay</surname><given-names>AA</given-names></name><name><surname>Connolly</surname><given-names>MD</given-names></name><name><surname>Reichner</surname><given-names>JS</given-names></name><name><surname>Albina</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice</article-title><source>Journal of Leukocyte Biology</source><volume>83</volume><fpage>64</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1189/jlb.0407247</pub-id><pub-id pub-id-type="pmid">17884993</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalton</surname><given-names>DK</given-names></name><name><surname>Pitts-Meek</surname><given-names>S</given-names></name><name><surname>Keshav</surname><given-names>S</given-names></name><name><surname>Figari</surname><given-names>IS</given-names></name><name><surname>Bradley</surname><given-names>A</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Multiple defects of immune cell function in mice with disrupted interferon-gamma genes</article-title><source>Science</source><volume>259</volume><fpage>1739</fpage><lpage>1742</lpage><pub-id pub-id-type="doi">10.1126/science.8456300</pub-id><pub-id pub-id-type="pmid">8456300</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>S</given-names></name><name><surname>Crotta</surname><given-names>S</given-names></name><name><surname>McCabe</surname><given-names>TM</given-names></name><name><surname>Wack</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pathogenic potential of interferon αβ in acute influenza infection</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>3864</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms4864</pub-id><pub-id pub-id-type="pmid">24844667</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deane</surname><given-names>JA</given-names></name><name><surname>Pisitkun</surname><given-names>P</given-names></name><name><surname>Barrett</surname><given-names>RS</given-names></name><name><surname>Feigenbaum</surname><given-names>L</given-names></name><name><surname>Town</surname><given-names>T</given-names></name><name><surname>Ward</surname><given-names>JMM</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Bolland</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation</article-title><source>Immunity</source><volume>27</volume><fpage>801</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2007.09.009</pub-id><pub-id pub-id-type="pmid">17997333</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeKoter</surname><given-names>RP</given-names></name><name><surname>Walsh</surname><given-names>JC</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>PU.1 regulates both cytokine-dependent proliferation and differentiation of granulocyte/macrophage progenitors</article-title><source>The EMBO Journal</source><volume>17</volume><fpage>4456</fpage><lpage>4468</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.15.4456</pub-id><pub-id pub-id-type="pmid">9687512</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feyerabend</surname><given-names>TB</given-names></name><name><surname>Weiser</surname><given-names>A</given-names></name><name><surname>Tietz</surname><given-names>A</given-names></name><name><surname>Stassen</surname><given-names>M</given-names></name><name><surname>Harris</surname><given-names>N</given-names></name><name><surname>Kopf</surname><given-names>M</given-names></name><name><surname>Radermacher</surname><given-names>P</given-names></name><name><surname>Möller</surname><given-names>P</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name><name><surname>Fehling</surname><given-names>HJ</given-names></name><name><surname>Rodewald</surname><given-names>H-R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cre-mediated cell ablation contests mast cell contribution in models of antibody- and T cell-mediated autoimmunity</article-title><source>Immunity</source><volume>35</volume><fpage>832</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.09.015</pub-id><pub-id pub-id-type="pmid">22101159</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamrekelashvili</surname><given-names>J</given-names></name><name><surname>Kapanadze</surname><given-names>T</given-names></name><name><surname>Sablotny</surname><given-names>S</given-names></name><name><surname>Ratiu</surname><given-names>C</given-names></name><name><surname>Dastagir</surname><given-names>K</given-names></name><name><surname>Lochner</surname><given-names>M</given-names></name><name><surname>Karbach</surname><given-names>S</given-names></name><name><surname>Wenzel</surname><given-names>P</given-names></name><name><surname>Sitnow</surname><given-names>A</given-names></name><name><surname>Fleig</surname><given-names>S</given-names></name><name><surname>Sparwasser</surname><given-names>T</given-names></name><name><surname>Kalinke</surname><given-names>U</given-names></name><name><surname>Holzmann</surname><given-names>B</given-names></name><name><surname>Haller</surname><given-names>H</given-names></name><name><surname>Limbourg</surname><given-names>FP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Notch and TLR signaling coordinate monocyte cell fate and inflammation</article-title><source>eLife</source><volume>9</volume><elocation-id>e57007</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.57007</pub-id><pub-id pub-id-type="pmid">32723480</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geissmann</surname><given-names>F</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Blood monocytes consist of two principal subsets with distinct migratory properties</article-title><source>Immunity</source><volume>19</volume><fpage>71</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/s1074-7613(03)00174-2</pub-id><pub-id pub-id-type="pmid">12871640</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginhoux</surname><given-names>F</given-names></name><name><surname>Guilliams</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tissue-resident macrophage ontogeny and homeostasis</article-title><source>Immunity</source><volume>44</volume><fpage>439</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.02.024</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goritzka</surname><given-names>M</given-names></name><name><surname>Makris</surname><given-names>S</given-names></name><name><surname>Kausar</surname><given-names>F</given-names></name><name><surname>Durant</surname><given-names>LR</given-names></name><name><surname>Pereira</surname><given-names>C</given-names></name><name><surname>Kumagai</surname><given-names>Y</given-names></name><name><surname>Culley</surname><given-names>FJ</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Johansson</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Alveolar macrophage-derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes</article-title><source>The Journal of Experimental Medicine</source><volume>212</volume><fpage>699</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1084/jem.20140825</pub-id><pub-id pub-id-type="pmid">25897172</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Göthert</surname><given-names>JR</given-names></name><name><surname>Gustin</surname><given-names>SE</given-names></name><name><surname>Hall</surname><given-names>MA</given-names></name><name><surname>Green</surname><given-names>AR</given-names></name><name><surname>Göttgens</surname><given-names>B</given-names></name><name><surname>Izon</surname><given-names>DJ</given-names></name><name><surname>Begley</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>In vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis</article-title><source>Blood</source><volume>105</volume><fpage>2724</fpage><lpage>2732</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-08-3037</pub-id><pub-id pub-id-type="pmid">15598809</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grainger</surname><given-names>JR</given-names></name><name><surname>Wohlfert</surname><given-names>EA</given-names></name><name><surname>Fuss</surname><given-names>IJ</given-names></name><name><surname>Bouladoux</surname><given-names>N</given-names></name><name><surname>Askenase</surname><given-names>MH</given-names></name><name><surname>Legrand</surname><given-names>F</given-names></name><name><surname>Koo</surname><given-names>LY</given-names></name><name><surname>Brenchley</surname><given-names>JM</given-names></name><name><surname>Fraser</surname><given-names>IDC</given-names></name><name><surname>Belkaid</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Inflammatory monocytes regulate pathologic responses to commensals during acute gastrointestinal infection</article-title><source>Nature Medicine</source><volume>19</volume><fpage>713</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1038/nm.3189</pub-id><pub-id pub-id-type="pmid">23708291</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haist</surname><given-names>KC</given-names></name><name><surname>Burrack</surname><given-names>KS</given-names></name><name><surname>Davenport</surname><given-names>BJ</given-names></name><name><surname>Morrison</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Inflammatory monocytes mediate control of acute alphavirus infection in mice</article-title><source>PLOS Pathogens</source><volume>13</volume><elocation-id>e1006748</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006748</pub-id><pub-id pub-id-type="pmid">29244871</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamers</surname><given-names>AAJ</given-names></name><name><surname>Dinh</surname><given-names>HQ</given-names></name><name><surname>Thomas</surname><given-names>GD</given-names></name><name><surname>Marcovecchio</surname><given-names>P</given-names></name><name><surname>Blatchley</surname><given-names>A</given-names></name><name><surname>Nakao</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>McSkimming</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>AM</given-names></name><name><surname>Nguyen</surname><given-names>AT</given-names></name><name><surname>McNamara</surname><given-names>CA</given-names></name><name><surname>Hedrick</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Human monocyte heterogeneity as revealed by high-dimensional mass cytometry</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>39</volume><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.118.311022</pub-id><pub-id pub-id-type="pmid">30580568</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Z</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Homeostasis of peripheral B cells in the absence of B cell influx from the bone marrow</article-title><source>The Journal of Experimental Medicine</source><volume>194</volume><fpage>1151</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1084/jem.194.8.1151</pub-id><pub-id pub-id-type="pmid">11602643</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemmi</surname><given-names>H</given-names></name><name><surname>Kaisho</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>O</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Sanjo</surname><given-names>H</given-names></name><name><surname>Hoshino</surname><given-names>K</given-names></name><name><surname>Horiuchi</surname><given-names>T</given-names></name><name><surname>Tomizawa</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway</article-title><source>Nature Immunology</source><volume>3</volume><fpage>196</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1038/ni758</pub-id><pub-id pub-id-type="pmid">11812998</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herold</surname><given-names>S</given-names></name><name><surname>Steinmueller</surname><given-names>M</given-names></name><name><surname>von Wulffen</surname><given-names>W</given-names></name><name><surname>Cakarova</surname><given-names>L</given-names></name><name><surname>Pinto</surname><given-names>R</given-names></name><name><surname>Pleschka</surname><given-names>S</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Kuziel</surname><given-names>WA</given-names></name><name><surname>Corazza</surname><given-names>N</given-names></name><name><surname>Brunner</surname><given-names>T</given-names></name><name><surname>Seeger</surname><given-names>W</given-names></name><name><surname>Lohmeyer</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand</article-title><source>The Journal of Experimental Medicine</source><volume>205</volume><fpage>3065</fpage><lpage>3077</lpage><pub-id pub-id-type="doi">10.1084/jem.20080201</pub-id><pub-id pub-id-type="pmid">19064696</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>SY</given-names></name><name><surname>Hertzog</surname><given-names>PJ</given-names></name><name><surname>Holland</surname><given-names>KA</given-names></name><name><surname>Sumarsono</surname><given-names>SH</given-names></name><name><surname>Tymms</surname><given-names>MJ</given-names></name><name><surname>Hamilton</surname><given-names>JA</given-names></name><name><surname>Whitty</surname><given-names>G</given-names></name><name><surname>Bertoncello</surname><given-names>I</given-names></name><name><surname>Kola</surname><given-names>I</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>A null mutation in the gene encoding A type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses</article-title><source>PNAS</source><volume>92</volume><fpage>11284</fpage><lpage>11288</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.24.11284</pub-id><pub-id pub-id-type="pmid">7479980</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iannitti</surname><given-names>RG</given-names></name><name><surname>Napolioni</surname><given-names>V</given-names></name><name><surname>Oikonomou</surname><given-names>V</given-names></name><name><surname>De Luca</surname><given-names>A</given-names></name><name><surname>Galosi</surname><given-names>C</given-names></name><name><surname>Pariano</surname><given-names>M</given-names></name><name><surname>Massi-Benedetti</surname><given-names>C</given-names></name><name><surname>Borghi</surname><given-names>M</given-names></name><name><surname>Puccetti</surname><given-names>M</given-names></name><name><surname>Lucidi</surname><given-names>V</given-names></name><name><surname>Colombo</surname><given-names>C</given-names></name><name><surname>Fiscarelli</surname><given-names>E</given-names></name><name><surname>Lass-Flörl</surname><given-names>C</given-names></name><name><surname>Majo</surname><given-names>F</given-names></name><name><surname>Cariani</surname><given-names>L</given-names></name><name><surname>Russo</surname><given-names>M</given-names></name><name><surname>Porcaro</surname><given-names>L</given-names></name><name><surname>Ricciotti</surname><given-names>G</given-names></name><name><surname>Ellemunter</surname><given-names>H</given-names></name><name><surname>Ratclif</surname><given-names>L</given-names></name><name><surname>De Benedictis</surname><given-names>FM</given-names></name><name><surname>Talesa</surname><given-names>VN</given-names></name><name><surname>Dinarello</surname><given-names>CA</given-names></name><name><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name><surname>Romani</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>10791</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms10791</pub-id><pub-id pub-id-type="pmid">26972847</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iijima</surname><given-names>N</given-names></name><name><surname>Mattei</surname><given-names>LM</given-names></name><name><surname>Iwasaki</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue</article-title><source>PNAS</source><volume>108</volume><fpage>284</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1073/pnas.1005201108</pub-id><pub-id pub-id-type="pmid">21173243</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Aliberti</surname><given-names>J</given-names></name><name><surname>Graemmel</surname><given-names>P</given-names></name><name><surname>Sunshine</surname><given-names>MJ</given-names></name><name><surname>Kreutzberg</surname><given-names>GW</given-names></name><name><surname>Sher</surname><given-names>A</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion</article-title><source>Molecular and Cellular Biology</source><volume>20</volume><fpage>4106</fpage><lpage>4114</lpage><pub-id pub-id-type="doi">10.1128/MCB.20.11.4106-4114.2000</pub-id><pub-id pub-id-type="pmid">10805752</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>H</given-names></name><name><surname>Mithal</surname><given-names>DS</given-names></name><name><surname>Park</surname><given-names>JE</given-names></name><name><surname>Miller</surname><given-names>RJ</given-names></name><name><surname>Harrison</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Localized CCR2 activation in the bone marrow niche mobilizes monocytes by desensitizing CXCR4</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0128387</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0128387</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolter</surname><given-names>J</given-names></name><name><surname>Feuerstein</surname><given-names>R</given-names></name><name><surname>Zeis</surname><given-names>P</given-names></name><name><surname>Hagemeyer</surname><given-names>N</given-names></name><name><surname>Paterson</surname><given-names>N</given-names></name><name><surname>d’Errico</surname><given-names>P</given-names></name><name><surname>Baasch</surname><given-names>S</given-names></name><name><surname>Amann</surname><given-names>L</given-names></name><name><surname>Masuda</surname><given-names>T</given-names></name><name><surname>Lösslein</surname><given-names>A</given-names></name><name><surname>Gharun</surname><given-names>K</given-names></name><name><surname>Meyer-Luehmann</surname><given-names>M</given-names></name><name><surname>Waskow</surname><given-names>C</given-names></name><name><surname>Franzke</surname><given-names>C-W</given-names></name><name><surname>Grün</surname><given-names>D</given-names></name><name><surname>Lämmermann</surname><given-names>T</given-names></name><name><surname>Prinz</surname><given-names>M</given-names></name><name><surname>Henneke</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A subset of skin macrophages contributes to the surveillance and regeneration of local nerves</article-title><source>Immunity</source><volume>50</volume><fpage>1482</fpage><lpage>1497</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.05.009</pub-id><pub-id pub-id-type="pmid">31201094</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuriakose</surname><given-names>J</given-names></name><name><surname>Redecke</surname><given-names>V</given-names></name><name><surname>Guy</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Ippagunta</surname><given-names>SK</given-names></name><name><surname>Tillman</surname><given-names>H</given-names></name><name><surname>Walker</surname><given-names>PD</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Häcker</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Patrolling monocytes promote the pathogenesis of early lupus-like glomerulonephritis</article-title><source>The Journal of Clinical Investigation</source><volume>129</volume><fpage>2251</fpage><lpage>2265</lpage><pub-id pub-id-type="doi">10.1172/JCI125116</pub-id><pub-id pub-id-type="pmid">31033479</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landsman</surname><given-names>L</given-names></name><name><surname>Bar-On</surname><given-names>L</given-names></name><name><surname>Zernecke</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Krauthgamer</surname><given-names>R</given-names></name><name><surname>Shagdarsuren</surname><given-names>E</given-names></name><name><surname>Lira</surname><given-names>SA</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name><name><surname>Weber</surname><given-names>C</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival</article-title><source>Blood</source><volume>113</volume><fpage>963</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-07-170787</pub-id><pub-id pub-id-type="pmid">18971423</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazear</surname><given-names>HM</given-names></name><name><surname>Nice</surname><given-names>TJ</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Interferon-λ: immune functions at barrier surfaces and beyond</article-title><source>Immunity</source><volume>43</volume><fpage>15</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.07.001</pub-id><pub-id pub-id-type="pmid">26200010</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DCP</given-names></name><name><surname>Harker</surname><given-names>JAE</given-names></name><name><surname>Tregoning</surname><given-names>JS</given-names></name><name><surname>Atabani</surname><given-names>SF</given-names></name><name><surname>Johansson</surname><given-names>C</given-names></name><name><surname>Schwarze</surname><given-names>J</given-names></name><name><surname>Openshaw</surname><given-names>PJM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection</article-title><source>Journal of Virology</source><volume>84</volume><fpage>8790</fpage><lpage>8798</lpage><pub-id pub-id-type="doi">10.1128/JVI.00796-10</pub-id><pub-id pub-id-type="pmid">20573822</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>KL</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Ramsburg</surname><given-names>E</given-names></name><name><surname>Gunn</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality</article-title><source>Journal of Immunology</source><volume>180</volume><fpage>2562</fpage><lpage>2572</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.4.2562</pub-id><pub-id pub-id-type="pmid">18250467</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>ER</given-names></name><name><surname>Menon</surname><given-names>M</given-names></name><name><surname>Knight</surname><given-names>SB</given-names></name><name><surname>Konkel</surname><given-names>JE</given-names></name><name><surname>Jagger</surname><given-names>C</given-names></name><name><surname>Shaw</surname><given-names>TN</given-names></name><name><surname>Krishnan</surname><given-names>S</given-names></name><name><surname>Rattray</surname><given-names>M</given-names></name><name><surname>Ustianowski</surname><given-names>A</given-names></name><name><surname>Bakerly</surname><given-names>ND</given-names></name><name><surname>Dark</surname><given-names>P</given-names></name><name><surname>Lord</surname><given-names>G</given-names></name><name><surname>Simpson</surname><given-names>A</given-names></name><name><surname>Felton</surname><given-names>T</given-names></name><name><surname>Ho</surname><given-names>L-P</given-names></name><collab>NIHR Respiratory TRC</collab><name><surname>Feldmann</surname><given-names>M</given-names></name><collab>CIRCO</collab><name><surname>Grainger</surname><given-names>JR</given-names></name><name><surname>Hussell</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19</article-title><source>Science Immunology</source><volume>5</volume><elocation-id>eabd6197</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abd6197</pub-id><pub-id pub-id-type="pmid">32943497</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menezes</surname><given-names>S</given-names></name><name><surname>Melandri</surname><given-names>D</given-names></name><name><surname>Anselmi</surname><given-names>G</given-names></name><name><surname>Perchet</surname><given-names>T</given-names></name><name><surname>Loschko</surname><given-names>J</given-names></name><name><surname>Dubrot</surname><given-names>J</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Gautier</surname><given-names>EL</given-names></name><name><surname>Hugues</surname><given-names>S</given-names></name><name><surname>Longhi</surname><given-names>MP</given-names></name><name><surname>Henry</surname><given-names>JY</given-names></name><name><surname>Quezada</surname><given-names>SA</given-names></name><name><surname>Lauvau</surname><given-names>G</given-names></name><name><surname>Lennon-Duménil</surname><given-names>A-M</given-names></name><name><surname>Gutiérrez-Martínez</surname><given-names>E</given-names></name><name><surname>Bessis</surname><given-names>A</given-names></name><name><surname>Gomez-Perdiguero</surname><given-names>E</given-names></name><name><surname>Jacome-Galarza</surname><given-names>CE</given-names></name><name><surname>Garner</surname><given-names>H</given-names></name><name><surname>Geissmann</surname><given-names>F</given-names></name><name><surname>Golub</surname><given-names>R</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name><name><surname>Guermonprez</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The Heterogeneity of Ly6Chi monocytes controls their differentiation into iNOS+ macrophages or monocyte-derived dendritic cells</article-title><source>Immunity</source><volume>45</volume><fpage>1205</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.12.001</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mildner</surname><given-names>A</given-names></name><name><surname>Schönheit</surname><given-names>J</given-names></name><name><surname>Giladi</surname><given-names>A</given-names></name><name><surname>David</surname><given-names>E</given-names></name><name><surname>Lara-Astiaso</surname><given-names>D</given-names></name><name><surname>Lorenzo-Vivas</surname><given-names>E</given-names></name><name><surname>Paul</surname><given-names>F</given-names></name><name><surname>Chappell-Maor</surname><given-names>L</given-names></name><name><surname>Priller</surname><given-names>J</given-names></name><name><surname>Leutz</surname><given-names>A</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genomic characterization of murine monocytes reveals C/EBPβ transcription factor dependence of Ly6C − cells</article-title><source>Immunity</source><volume>46</volume><fpage>849</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.04.018</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitroulis</surname><given-names>I</given-names></name><name><surname>Ruppova</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>L-S</given-names></name><name><surname>Grzybek</surname><given-names>M</given-names></name><name><surname>Grinenko</surname><given-names>T</given-names></name><name><surname>Eugster</surname><given-names>A</given-names></name><name><surname>Troullinaki</surname><given-names>M</given-names></name><name><surname>Palladini</surname><given-names>A</given-names></name><name><surname>Kourtzelis</surname><given-names>I</given-names></name><name><surname>Chatzigeorgiou</surname><given-names>A</given-names></name><name><surname>Schlitzer</surname><given-names>A</given-names></name><name><surname>Beyer</surname><given-names>M</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name><name><surname>Isermann</surname><given-names>B</given-names></name><name><surname>Lesche</surname><given-names>M</given-names></name><name><surname>Petzold</surname><given-names>A</given-names></name><name><surname>Simons</surname><given-names>K</given-names></name><name><surname>Henry</surname><given-names>I</given-names></name><name><surname>Dahl</surname><given-names>A</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Wielockx</surname><given-names>B</given-names></name><name><surname>Zamboni</surname><given-names>N</given-names></name><name><surname>Mirtschink</surname><given-names>P</given-names></name><name><surname>Coskun</surname><given-names>Ü</given-names></name><name><surname>Hajishengallis</surname><given-names>G</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Chavakis</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Modulation of myelopoiesis progenitors is an integral component of trained immunity</article-title><source>Cell</source><volume>172</volume><fpage>147</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.11.034</pub-id><pub-id pub-id-type="pmid">29328910</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagai</surname><given-names>Y</given-names></name><name><surname>Garrett</surname><given-names>KP</given-names></name><name><surname>Ohta</surname><given-names>S</given-names></name><name><surname>Bahrun</surname><given-names>U</given-names></name><name><surname>Kouro</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Takatsu</surname><given-names>K</given-names></name><name><surname>Kincade</surname><given-names>PW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment</article-title><source>Immunity</source><volume>24</volume><fpage>801</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2006.04.008</pub-id><pub-id pub-id-type="pmid">16782035</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paixão</surname><given-names>ES</given-names></name><name><surname>Teixeira</surname><given-names>MG</given-names></name><name><surname>Rodrigues</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Zika, chikungunya and dengue: the causes and threats of new and re-emerging arboviral diseases</article-title><source>BMJ Global Health</source><volume>3</volume><elocation-id>e000530</elocation-id><pub-id pub-id-type="doi">10.1136/bmjgh-2017-000530</pub-id><pub-id pub-id-type="pmid">29435366</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>AA</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Fullerton</surname><given-names>JN</given-names></name><name><surname>Boelen</surname><given-names>L</given-names></name><name><surname>Rongvaux</surname><given-names>A</given-names></name><name><surname>Maini</surname><given-names>AA</given-names></name><name><surname>Bigley</surname><given-names>V</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Gilroy</surname><given-names>DW</given-names></name><name><surname>Asquith</surname><given-names>B</given-names></name><name><surname>Macallan</surname><given-names>D</given-names></name><name><surname>Yona</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The fate and lifespan of human monocyte subsets in steady state and systemic inflammation</article-title><source>The Journal of Experimental Medicine</source><volume>214</volume><fpage>1913</fpage><lpage>1923</lpage><pub-id pub-id-type="doi">10.1084/jem.20170355</pub-id><pub-id pub-id-type="pmid">28606987</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>DF</given-names></name><name><surname>Peiró</surname><given-names>T</given-names></name><name><surname>Bruno</surname><given-names>N</given-names></name><name><surname>Vuononvirta</surname><given-names>J</given-names></name><name><surname>Akthar</surname><given-names>S</given-names></name><name><surname>Puttur</surname><given-names>F</given-names></name><name><surname>Pyle</surname><given-names>CJ</given-names></name><name><surname>Suveizdytė</surname><given-names>K</given-names></name><name><surname>Walker</surname><given-names>SA</given-names></name><name><surname>Singanayagam</surname><given-names>A</given-names></name><name><surname>Carlin</surname><given-names>LM</given-names></name><name><surname>Gregory</surname><given-names>LG</given-names></name><name><surname>Lloyd</surname><given-names>CM</given-names></name><name><surname>Snelgrove</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Neutrophils restrain allergic airway inflammation by limiting ILC2 function and monocyte-dendritic cell antigen presentation</article-title><source>Science Immunology</source><volume>4</volume><elocation-id>eaax7006</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aax7006</pub-id><pub-id pub-id-type="pmid">31704734</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Percie du Sert</surname><given-names>N</given-names></name><name><surname>Hurst</surname><given-names>V</given-names></name><name><surname>Ahluwalia</surname><given-names>A</given-names></name><name><surname>Alam</surname><given-names>S</given-names></name><name><surname>Avey</surname><given-names>MT</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Browne</surname><given-names>WJ</given-names></name><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Cuthill</surname><given-names>IC</given-names></name><name><surname>Dirnagl</surname><given-names>U</given-names></name><name><surname>Emerson</surname><given-names>M</given-names></name><name><surname>Garner</surname><given-names>P</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name><name><surname>Howells</surname><given-names>DW</given-names></name><name><surname>Karp</surname><given-names>NA</given-names></name><name><surname>Lazic</surname><given-names>SE</given-names></name><name><surname>Lidster</surname><given-names>K</given-names></name><name><surname>MacCallum</surname><given-names>CJ</given-names></name><name><surname>Macleod</surname><given-names>M</given-names></name><name><surname>Pearl</surname><given-names>EJ</given-names></name><name><surname>Petersen</surname><given-names>OH</given-names></name><name><surname>Rawle</surname><given-names>F</given-names></name><name><surname>Reynolds</surname><given-names>P</given-names></name><name><surname>Rooney</surname><given-names>K</given-names></name><name><surname>Sena</surname><given-names>ES</given-names></name><name><surname>Silberberg</surname><given-names>SD</given-names></name><name><surname>Steckler</surname><given-names>T</given-names></name><name><surname>Würbel</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research</article-title><source>PLOS Biology</source><volume>18</volume><elocation-id>e3000410</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3000410</pub-id><pub-id pub-id-type="pmid">32663219</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietras</surname><given-names>EM</given-names></name><name><surname>Mirantes-Barbeito</surname><given-names>C</given-names></name><name><surname>Fong</surname><given-names>S</given-names></name><name><surname>Loeffler</surname><given-names>D</given-names></name><name><surname>Kovtonyuk</surname><given-names>LV</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Lakshminarasimhan</surname><given-names>R</given-names></name><name><surname>Chin</surname><given-names>CP</given-names></name><name><surname>Techner</surname><given-names>J-M</given-names></name><name><surname>Will</surname><given-names>B</given-names></name><name><surname>Nerlov</surname><given-names>C</given-names></name><name><surname>Steidl</surname><given-names>U</given-names></name><name><surname>Manz</surname><given-names>MG</given-names></name><name><surname>Schroeder</surname><given-names>T</given-names></name><name><surname>Passegué</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal</article-title><source>Nature Cell Biology</source><volume>18</volume><fpage>607</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1038/ncb3346</pub-id><pub-id pub-id-type="pmid">27111842</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radu</surname><given-names>M</given-names></name><name><surname>Chernoff</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>An in vivo assay to test blood vessel permeability</article-title><source>Journal of Visualized Experiments</source><volume>1</volume><elocation-id>e50062</elocation-id><pub-id pub-id-type="doi">10.3791/50062</pub-id><pub-id pub-id-type="pmid">23524912</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saederup</surname><given-names>N</given-names></name><name><surname>Cardona</surname><given-names>AE</given-names></name><name><surname>Croft</surname><given-names>K</given-names></name><name><surname>Mizutani</surname><given-names>M</given-names></name><name><surname>Cotleur</surname><given-names>AC</given-names></name><name><surname>Tsou</surname><given-names>CL</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name><name><surname>Charo</surname><given-names>IF</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e13693</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0013693</pub-id><pub-id pub-id-type="pmid">21060874</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Nakagawa</surname><given-names>K</given-names></name><name><surname>Sugihara</surname><given-names>F</given-names></name><name><surname>Kuwahara</surname><given-names>R</given-names></name><name><surname>Ashihara</surname><given-names>M</given-names></name><name><surname>Yamane</surname><given-names>F</given-names></name><name><surname>Minowa</surname><given-names>Y</given-names></name><name><surname>Fukushima</surname><given-names>K</given-names></name><name><surname>Ebina</surname><given-names>I</given-names></name><name><surname>Yoshioka</surname><given-names>Y</given-names></name><name><surname>Kumanogoh</surname><given-names>A</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Identification of an atypical monocyte and committed progenitor involved in fibrosis</article-title><source>Nature</source><volume>541</volume><fpage>96</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1038/nature20611</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>J-Y</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulte-Schrepping</surname><given-names>J</given-names></name><name><surname>Reusch</surname><given-names>N</given-names></name><name><surname>Paclik</surname><given-names>D</given-names></name><name><surname>Baßler</surname><given-names>K</given-names></name><name><surname>Schlickeiser</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Krämer</surname><given-names>B</given-names></name><name><surname>Krammer</surname><given-names>T</given-names></name><name><surname>Brumhard</surname><given-names>S</given-names></name><name><surname>Bonaguro</surname><given-names>L</given-names></name><name><surname>De Domenico</surname><given-names>E</given-names></name><name><surname>Wendisch</surname><given-names>D</given-names></name><name><surname>Grasshoff</surname><given-names>M</given-names></name><name><surname>Kapellos</surname><given-names>TS</given-names></name><name><surname>Beckstette</surname><given-names>M</given-names></name><name><surname>Pecht</surname><given-names>T</given-names></name><name><surname>Saglam</surname><given-names>A</given-names></name><name><surname>Dietrich</surname><given-names>O</given-names></name><name><surname>Mei</surname><given-names>HE</given-names></name><name><surname>Schulz</surname><given-names>AR</given-names></name><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Kunkel</surname><given-names>D</given-names></name><name><surname>Vafadarnejad</surname><given-names>E</given-names></name><name><surname>Xu</surname><given-names>C-J</given-names></name><name><surname>Horne</surname><given-names>A</given-names></name><name><surname>Herbert</surname><given-names>M</given-names></name><name><surname>Drews</surname><given-names>A</given-names></name><name><surname>Thibeault</surname><given-names>C</given-names></name><name><surname>Pfeiffer</surname><given-names>M</given-names></name><name><surname>Hippenstiel</surname><given-names>S</given-names></name><name><surname>Hocke</surname><given-names>A</given-names></name><name><surname>Müller-Redetzky</surname><given-names>H</given-names></name><name><surname>Heim</surname><given-names>K-M</given-names></name><name><surname>Machleidt</surname><given-names>F</given-names></name><name><surname>Uhrig</surname><given-names>A</given-names></name><name><surname>Bosquillon de Jarcy</surname><given-names>L</given-names></name><name><surname>Jürgens</surname><given-names>L</given-names></name><name><surname>Stegemann</surname><given-names>M</given-names></name><name><surname>Glösenkamp</surname><given-names>CR</given-names></name><name><surname>Volk</surname><given-names>H-D</given-names></name><name><surname>Goffinet</surname><given-names>C</given-names></name><name><surname>Landthaler</surname><given-names>M</given-names></name><name><surname>Wyler</surname><given-names>E</given-names></name><name><surname>Georg</surname><given-names>P</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Dang-Heine</surname><given-names>C</given-names></name><name><surname>Neuwinger</surname><given-names>N</given-names></name><name><surname>Kappert</surname><given-names>K</given-names></name><name><surname>Tauber</surname><given-names>R</given-names></name><name><surname>Corman</surname><given-names>V</given-names></name><name><surname>Raabe</surname><given-names>J</given-names></name><name><surname>Kaiser</surname><given-names>KM</given-names></name><name><surname>Vinh</surname><given-names>MT</given-names></name><name><surname>Rieke</surname><given-names>G</given-names></name><name><surname>Meisel</surname><given-names>C</given-names></name><name><surname>Ulas</surname><given-names>T</given-names></name><name><surname>Becker</surname><given-names>M</given-names></name><name><surname>Geffers</surname><given-names>R</given-names></name><name><surname>Witzenrath</surname><given-names>M</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>Suttorp</surname><given-names>N</given-names></name><name><surname>von Kalle</surname><given-names>C</given-names></name><name><surname>Kurth</surname><given-names>F</given-names></name><name><surname>Händler</surname><given-names>K</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Aschenbrenner</surname><given-names>AC</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Nattermann</surname><given-names>J</given-names></name><name><surname>Sawitzki</surname><given-names>B</given-names></name><name><surname>Saliba</surname><given-names>A-E</given-names></name><name><surname>Sander</surname><given-names>LE</given-names></name><name><surname>Angelov</surname><given-names>A</given-names></name><name><surname>Bals</surname><given-names>R</given-names></name><name><surname>Bartholomäus</surname><given-names>A</given-names></name><name><surname>Becker</surname><given-names>A</given-names></name><name><surname>Bezdan</surname><given-names>D</given-names></name><name><surname>Bonifacio</surname><given-names>E</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><name><surname>Clavel</surname><given-names>T</given-names></name><name><surname>Colome-Tatche</surname><given-names>M</given-names></name><name><surname>Diefenbach</surname><given-names>A</given-names></name><name><surname>Dilthey</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>N</given-names></name><name><surname>Förstner</surname><given-names>K</given-names></name><name><surname>Frick</surname><given-names>J-S</given-names></name><name><surname>Gagneur</surname><given-names>J</given-names></name><name><surname>Goesmann</surname><given-names>A</given-names></name><name><surname>Hain</surname><given-names>T</given-names></name><name><surname>Hummel</surname><given-names>M</given-names></name><name><surname>Janssen</surname><given-names>S</given-names></name><name><surname>Kalinowski</surname><given-names>J</given-names></name><name><surname>Kallies</surname><given-names>R</given-names></name><name><surname>Kehr</surname><given-names>B</given-names></name><name><surname>Keller</surname><given-names>A</given-names></name><name><surname>Kim-Hellmuth</surname><given-names>S</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Kohlbacher</surname><given-names>O</given-names></name><name><surname>Korbel</surname><given-names>JO</given-names></name><name><surname>Kurth</surname><given-names>I</given-names></name><name><surname>Landthaler</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Ludwig</surname><given-names>K</given-names></name><name><surname>Makarewicz</surname><given-names>O</given-names></name><name><surname>Marz</surname><given-names>M</given-names></name><name><surname>McHardy</surname><given-names>A</given-names></name><name><surname>Mertes</surname><given-names>C</given-names></name><name><surname>Nöthen</surname><given-names>M</given-names></name><name><surname>Nürnberg</surname><given-names>P</given-names></name><name><surname>Ohler</surname><given-names>U</given-names></name><name><surname>Ossowski</surname><given-names>S</given-names></name><name><surname>Overmann</surname><given-names>J</given-names></name><name><surname>Peter</surname><given-names>S</given-names></name><name><surname>Pfeffer</surname><given-names>K</given-names></name><name><surname>Poetsch</surname><given-names>AR</given-names></name><name><surname>Pühler</surname><given-names>A</given-names></name><name><surname>Rajewsky</surname><given-names>N</given-names></name><name><surname>Ralser</surname><given-names>M</given-names></name><name><surname>Rieß</surname><given-names>O</given-names></name><name><surname>Ripke</surname><given-names>S</given-names></name><name><surname>Nunes da Rocha</surname><given-names>U</given-names></name><name><surname>Rosenstiel</surname><given-names>P</given-names></name><name><surname>Saliba</surname><given-names>A-E</given-names></name><name><surname>Sander</surname><given-names>LE</given-names></name><name><surname>Sawitzki</surname><given-names>B</given-names></name><name><surname>Schiffer</surname><given-names>P</given-names></name><name><surname>Schulte</surname><given-names>E-C</given-names></name><name><surname>Schultze</surname><given-names>JL</given-names></name><name><surname>Sczyrba</surname><given-names>A</given-names></name><name><surname>Stegle</surname><given-names>O</given-names></name><name><surname>Stoye</surname><given-names>J</given-names></name><name><surname>Theis</surname><given-names>F</given-names></name><name><surname>Vehreschild</surname><given-names>J</given-names></name><name><surname>Vogel</surname><given-names>J</given-names></name><name><surname>von Kleist</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>A</given-names></name><name><surname>Walter</surname><given-names>J</given-names></name><name><surname>Wieczorek</surname><given-names>D</given-names></name><name><surname>Ziebuhr</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Severe COVID-19 Is marked by a dysregulated myeloid cell compartment</article-title><source>Cell</source><volume>182</volume><fpage>1419</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.08.001</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serbina</surname><given-names>NV</given-names></name><name><surname>Pamer</surname><given-names>EG</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2</article-title><source>Nature Immunology</source><volume>7</volume><fpage>311</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1038/ni1309</pub-id><pub-id pub-id-type="pmid">16462739</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serbina</surname><given-names>NV</given-names></name><name><surname>Hohl</surname><given-names>TM</given-names></name><name><surname>Cherny</surname><given-names>M</given-names></name><name><surname>Pamer</surname><given-names>EG</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Selective expansion of the monocytic lineage directed by bacterial infection</article-title><source>The Journal of Immunology</source><volume>183</volume><fpage>1900</fpage><lpage>1910</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0900612</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>C</given-names></name><name><surname>Pamer</surname><given-names>EG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Monocyte recruitment during infection and inflammation</article-title><source>Nature Reviews. Immunology</source><volume>11</volume><fpage>762</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1038/nri3070</pub-id><pub-id pub-id-type="pmid">21984070</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinkai</surname><given-names>Y</given-names></name><name><surname>Rathbun</surname><given-names>G</given-names></name><name><surname>Lam</surname><given-names>KP</given-names></name><name><surname>Oltz</surname><given-names>EM</given-names></name><name><surname>Stewart</surname><given-names>V</given-names></name><name><surname>Mendelsohn</surname><given-names>M</given-names></name><name><surname>Charron</surname><given-names>J</given-names></name><name><surname>Datta</surname><given-names>M</given-names></name><name><surname>Young</surname><given-names>F</given-names></name><name><surname>Stall</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement</article-title><source>Cell</source><volume>68</volume><fpage>855</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90029-c</pub-id><pub-id pub-id-type="pmid">1547487</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sioud</surname><given-names>M</given-names></name><name><surname>Fløisand</surname><given-names>Y</given-names></name><name><surname>Forfang</surname><given-names>L</given-names></name><name><surname>Lund-Johansen</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Signaling through toll-like receptor 7/8 induces the differentiation of Human Bone Marrow CD34+ Progenitor cells along the myeloid lineage</article-title><source>Journal of Molecular Biology</source><volume>364</volume><fpage>945</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2006.09.054</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solmaz</surname><given-names>G</given-names></name><name><surname>Puttur</surname><given-names>F</given-names></name><name><surname>Francozo</surname><given-names>M</given-names></name><name><surname>Lindenberg</surname><given-names>M</given-names></name><name><surname>Guderian</surname><given-names>M</given-names></name><name><surname>Swallow</surname><given-names>M</given-names></name><name><surname>Duhan</surname><given-names>V</given-names></name><name><surname>Khairnar</surname><given-names>V</given-names></name><name><surname>Kalinke</surname><given-names>U</given-names></name><name><surname>Ludewig</surname><given-names>B</given-names></name><name><surname>Clausen</surname><given-names>BE</given-names></name><name><surname>Wagner</surname><given-names>H</given-names></name><name><surname>Lang</surname><given-names>KS</given-names></name><name><surname>Sparwasser</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>TLR7 Controls VSV replication in CD169<sup>+</sup> SCS macrophages and associated viral neuroinvasion</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>466</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00466</pub-id><pub-id pub-id-type="pmid">30930901</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunderkötter</surname><given-names>C</given-names></name><name><surname>Nikolic</surname><given-names>T</given-names></name><name><surname>Dillon</surname><given-names>MJ</given-names></name><name><surname>Van Rooijen</surname><given-names>N</given-names></name><name><surname>Stehling</surname><given-names>M</given-names></name><name><surname>Drevets</surname><given-names>DA</given-names></name><name><surname>Leenen</surname><given-names>PJM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response</article-title><source>Journal of Immunology</source><volume>172</volume><fpage>4410</fpage><lpage>4417</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.7.4410</pub-id><pub-id pub-id-type="pmid">15034056</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swirski</surname><given-names>FK</given-names></name><name><surname>Nahrendorf</surname><given-names>M</given-names></name><name><surname>Etzrodt</surname><given-names>M</given-names></name><name><surname>Wildgruber</surname><given-names>M</given-names></name><name><surname>Cortez-Retamozo</surname><given-names>V</given-names></name><name><surname>Panizzi</surname><given-names>P</given-names></name><name><surname>Figueiredo</surname><given-names>J-L</given-names></name><name><surname>Kohler</surname><given-names>RH</given-names></name><name><surname>Chudnovskiy</surname><given-names>A</given-names></name><name><surname>Waterman</surname><given-names>P</given-names></name><name><surname>Aikawa</surname><given-names>E</given-names></name><name><surname>Mempel</surname><given-names>TR</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Pittet</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Identification of splenic reservoir monocytes and their deployment to inflammatory sites</article-title><source>Science</source><volume>325</volume><fpage>612</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1126/science.1175202</pub-id><pub-id pub-id-type="pmid">19644120</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takizawa</surname><given-names>H</given-names></name><name><surname>Boettcher</surname><given-names>S</given-names></name><name><surname>Manz</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Demand-adapted regulation of early hematopoiesis in infection and inflammation</article-title><source>Blood</source><volume>119</volume><fpage>2991</fpage><lpage>3002</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-12-380113</pub-id><pub-id pub-id-type="pmid">22246037</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsou</surname><given-names>CL</given-names></name><name><surname>Peters</surname><given-names>W</given-names></name><name><surname>Si</surname><given-names>Y</given-names></name><name><surname>Slaymaker</surname><given-names>S</given-names></name><name><surname>Aslanian</surname><given-names>AM</given-names></name><name><surname>Weisberg</surname><given-names>SP</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Charo</surname><given-names>IF</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites</article-title><source>Journal of Clinical Investigation</source><volume>117</volume><fpage>902</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1172/JCI29919</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner-Stokes</surname><given-names>T</given-names></name><name><surname>Garcia Diaz</surname><given-names>A</given-names></name><name><surname>Pinheiro</surname><given-names>D</given-names></name><name><surname>Prendecki</surname><given-names>M</given-names></name><name><surname>McAdoo</surname><given-names>SP</given-names></name><name><surname>Roufosse</surname><given-names>C</given-names></name><name><surname>Cook</surname><given-names>HT</given-names></name><name><surname>Pusey</surname><given-names>CD</given-names></name><name><surname>Woollard</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Live imaging of monocyte subsets in immune complex-mediated glomerulonephritis reveals distinct phenotypes and effector functions</article-title><source>Journal of the American Society of Nephrology</source><volume>31</volume><fpage>2523</fpage><lpage>2542</lpage><pub-id pub-id-type="doi">10.1681/ASN.2019121326</pub-id><pub-id pub-id-type="pmid">32868399</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulich</surname><given-names>T</given-names></name><name><surname>del Castillo</surname><given-names>J</given-names></name><name><surname>Watson</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>S</given-names></name><name><surname>Garnick</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>In vivo hematologic effects of recombinant human macrophage colony- stimulating factor</article-title><source>Blood</source><volume>75</volume><fpage>846</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1182/blood.V75.4.846.846</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varol</surname><given-names>C</given-names></name><name><surname>Landsman</surname><given-names>L</given-names></name><name><surname>Fogg</surname><given-names>DK</given-names></name><name><surname>Greenshtein</surname><given-names>L</given-names></name><name><surname>Gildor</surname><given-names>B</given-names></name><name><surname>Margalit</surname><given-names>R</given-names></name><name><surname>Kalchenko</surname><given-names>V</given-names></name><name><surname>Geissmann</surname><given-names>F</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Monocytes give rise to mucosal, but not splenic, conventional dendritic cells</article-title><source>The Journal of Experimental Medicine</source><volume>204</volume><fpage>171</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1084/jem.20061011</pub-id><pub-id pub-id-type="pmid">17190836</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wack</surname><given-names>A</given-names></name><name><surname>Terczyńska-Dyla</surname><given-names>E</given-names></name><name><surname>Hartmann</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Guarding the frontiers: the biology of type III interferons</article-title><source>Nature Immunology</source><volume>16</volume><fpage>802</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1038/ni.3212</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>CL</given-names></name><name><surname>Dempsey</surname><given-names>MH</given-names></name><name><surname>Ring</surname><given-names>CJA</given-names></name><name><surname>Kempson</surname><given-names>RE</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Gor</surname><given-names>D</given-names></name><name><surname>Snowden</surname><given-names>BW</given-names></name><name><surname>Tisdale</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Design and performance testing of quantitative realtime PCR assays for influenza A and B viral load measurement</article-title><source>Journal of Clinical</source><volume>29</volume><fpage>179</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/S1386-6532(03)00122-7</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>CW</given-names></name><name><surname>Woods</surname><given-names>TA</given-names></name><name><surname>Robertson</surname><given-names>SJ</given-names></name><name><surname>McNally</surname><given-names>KL</given-names></name><name><surname>Carmody</surname><given-names>AB</given-names></name><name><surname>Best</surname><given-names>SM</given-names></name><name><surname>Peterson</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cutting Edge: CCR2 Is not required for Ly6C<sup>hi</sup> Monocyte egress from the bone marrow but is necessary for migration within the brain in La Crosse Virus Encephalitis</article-title><source>Journal of Immunology</source><volume>200</volume><fpage>471</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1701230</pub-id><pub-id pub-id-type="pmid">29246952</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>AA</given-names></name><name><surname>Yáñez</surname><given-names>A</given-names></name><name><surname>Barman</surname><given-names>PK</given-names></name><name><surname>Goodridge</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The ontogeny of monocyte subsets</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>1642</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.01642</pub-id><pub-id pub-id-type="pmid">31379841</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wynn</surname><given-names>TA</given-names></name><name><surname>Vannella</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Macrophages in tissue repair, regeneration, and fibrosis</article-title><source>Immunity</source><volume>44</volume><fpage>450</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.02.015</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yáñez</surname><given-names>A</given-names></name><name><surname>Coetzee</surname><given-names>SG</given-names></name><name><surname>Olsson</surname><given-names>A</given-names></name><name><surname>Muench</surname><given-names>DE</given-names></name><name><surname>Berman</surname><given-names>BP</given-names></name><name><surname>Hazelett</surname><given-names>DJ</given-names></name><name><surname>Salomonis</surname><given-names>N</given-names></name><name><surname>Grimes</surname><given-names>HL</given-names></name><name><surname>Goodridge</surname><given-names>HS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Granulocyte-monocyte progenitors and monocyte-dendritic cell progenitors independently produce functionally distinct monocytes</article-title><source>Immunity</source><volume>47</volume><fpage>890</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.10.021</pub-id><pub-id pub-id-type="pmid">29166589</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yona</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>K-W</given-names></name><name><surname>Wolf</surname><given-names>Y</given-names></name><name><surname>Mildner</surname><given-names>A</given-names></name><name><surname>Varol</surname><given-names>D</given-names></name><name><surname>Breker</surname><given-names>M</given-names></name><name><surname>Strauss-Ayali</surname><given-names>D</given-names></name><name><surname>Viukov</surname><given-names>S</given-names></name><name><surname>Guilliams</surname><given-names>M</given-names></name><name><surname>Misharin</surname><given-names>A</given-names></name><name><surname>Hume</surname><given-names>DA</given-names></name><name><surname>Perlman</surname><given-names>H</given-names></name><name><surname>Malissen</surname><given-names>B</given-names></name><name><surname>Zelzer</surname><given-names>E</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis</article-title><source>Immunity</source><volume>38</volume><fpage>79</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.12.001</pub-id><pub-id pub-id-type="pmid">23273845</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Cantor</surname><given-names>AB</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Browne</surname><given-names>C</given-names></name><name><surname>Wells</surname><given-names>RA</given-names></name><name><surname>Fujiwara</surname><given-names>Y</given-names></name><name><surname>Orkin</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo</article-title><source>The Journal of Experimental Medicine</source><volume>195</volume><fpage>1387</fpage><lpage>1395</lpage><pub-id pub-id-type="doi">10.1084/jem.20020656</pub-id><pub-id pub-id-type="pmid">12045237</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85647.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Noble</surname><given-names>Paul W</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pammg90</institution-id><institution>Cedars-Sinai Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2023.02.06.527328" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2023.02.06.527328"/></front-stub><body><p>This work advances our understanding of TLR7 signalling at epithelial surfaces that drives monocytes expansion and its impact on viral responses. The evidence supporting this conclusion is solid, particularly data demonstrating TLR7 stimulation and the requirement for TLR7 in the monocyte expansion. The work will be of interest to immunologists and virologists.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85647.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Noble</surname><given-names>Paul W</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pammg90</institution-id><institution>Cedars-Sinai Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Grainger</surname><given-names>John R</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/027m9bs27</institution-id><institution>University of Manchester</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2023.02.06.527328">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2023.02.06.527328v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;TLR7 activation at epithelial barriers promotes emergency myelopoiesis and lung anti-viral immunity&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Paul Noble as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Both reviewers identified a few key aspects for revision. Please address them to the best of your ability.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Specific experiments that could increase the impact of this work and discussion points that could be clarified/reworded include:</p><p>1) Measurement of CSF-1 across the time course by protein in the serum/plasma of these mice, or in the bone marrow by RNA transcript, would rule in or out the most obvious candidate for the phenotype observed.</p><p>2) Inclusion of either further in vitro or in vivo experiments to demonstrate that the monocytes themselves are primed to respond differently to flu infection. Or rewording of the results/conclusion to better reflect the limitations of the experiments undertaken. For example, currently, the manuscript states: &quot;Similarly, the extravasation of monocytes in the lung of R848-treated mice limited the viral replication after infection with respiratory syncytial virus (RSV) (Figure 7E), an RNA virus responsible for infant hospitalizations in the developed world&quot;. Unless I am totally misunderstanding the experiment this figure does not even show that monocytes, let alone extravasation of monocytes, is important in the changes in protection.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. It is not clear from the figure legends if experiments were repeated or were a single study. This should be clarified in the manuscript.</p><p>2. Would recommend a more detailed phenotype of the respiratory viral pathogen lung responses. In particular, more detailed peripheral and lung immune phenotyping of monocytes and lung macrophages. This would better define the relationship of TLR7, myelopoiesis, and respiratory viral infection.</p><p>3. The images in Figure 6C are poor quality and hard to visualize. It is also not clear if they are intraparenchymal or intravascular.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85647.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Reviewer #1 (Recommendations for the authors):</p><p>Specific experiments that could increase the impact of this work and discussion points that could be clarified/reworded include:</p><p>1) Measurement of CSF-1 across the time course by protein in the serum/plasma of these mice, or in the bone marrow by RNA transcript, would rule in or out the most obvious candidate for the phenotype observed.</p></disp-quote><p>We appreciate the point raised by the reviewer and CSF-1 was investigated (it was one the most obvious candidates for the monocytosis), but the results were not informative or inconclusive, and thus we decided not to include them in the paper. For the benefit of the reviewers we have listed below the additional experiments that we have conducted:</p><list list-type="order"><list-item><p>Trascriptomic analysis of the whole skin using nCounter Gene Expression System (NanoString technology): no increase in the Csf1 transcript counts were found in the R848-treated skin, making implausible for CSF-1 to be the key local factor driving the monocytosis (see <xref ref-type="fig" rid="sa2fig1">Author response image 1A</xref>). We did not consider measuring the Csf1 transcript in the bone marrow as we were looking for a skin-derived soluble factor connecting local TLR7 stimulation and the emergency myelopoiesis.</p></list-item><list-item><p>Measurement of CSF-1 level in circulation. This analysis revealed increased serum levels of CSF-1 both after topical and intraperitoneal administration of R848 (see <xref ref-type="fig" rid="sa2fig1">Author response image 1B</xref>) making the involvement of CSF-1 unlikely as only activation of the TLR7 pathway at the skin barrier caused overt monocytosis, especially after 4 weeks of treatment.</p></list-item><list-item><p>Blocking of CSF1R using the Ki20227 inhibitor: these experiments had to be stopped prematurely due to respiratory distress in the animals.</p></list-item><list-item><p>Inhibition of the Glycoprotein 130 (gp130) protein that is part of the receptor signalling complexes for at least 8 cytokines (IL-6, IL-11, IL-27, LIF, CNTF, OSM, CT-1, and CLC) using the small-molecule SC144: these experiments had to be stopped after the second R848 treatment due to neurological toxicity of the compound (seizures).</p></list-item></list><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><p>(A) BALB/c mice (n=4 per group) received 2x topical ear treatments with 100ug R848, while vehicle mice received 2x treatments with acetone. Ear skin was harvested at 24 hours after the final treatment for transcriptomic analysis. Csf1 transcript counts shown are normalised to a panel of reference genes. Data represent a single experiment. (B) BALB/c mice (n=3 per group) received 100μg of R848 topically or I.P, 3x per week for 4 weeks. Control mice were given topical acetone. Serum CSF-1 levels were quantified by ELISA. Panel (A) was analysed by Mann-Whitney test; panel (B) by oneway ANOVA with Bonferroni’s multiple comparison test versus vehicle group. Data are the mean ± SEM; ns = non significant; p values are indicated.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85647-sa2-fig1-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>2) Inclusion of either further in vitro or in vivo experiments to demonstrate that the monocytes themselves are primed to respond differently to flu infection. Or rewording of the results/conclusion to better reflect the limitations of the experiments undertaken. For example, currently, the manuscript states: &quot;Similarly, the extravasation of monocytes in the lung of R848-treated mice limited the viral replication after infection with respiratory syncytial virus (RSV) (Figure 7E), an RNA virus responsible for infant hospitalizations in the developed world&quot;. Unless I am totally misunderstanding the experiment this figure does not even show that monocytes, let alone extravasation of monocytes, is important in the changes in protection.</p></disp-quote><p>The reviewer is correct and we apologise for the misleading sentence. We have rephrased this point in the main manuscript to reflect more accurately that our data show just a correlation and not a direct effect of extravasating monocytes on the local viral replication.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. It is not clear from the figure legends if experiments were repeated or were a single study. This should be clarified in the manuscript.</p></disp-quote><p>The number of repeated experiments is indicated at the end of each figure legend. When we have performed variable numbers, we have indicated the minimal number.</p><disp-quote content-type="editor-comment"><p>2. Would recommend a more detailed phenotype of the respiratory viral pathogen lung responses. In particular, more detailed peripheral and lung immune phenotyping of monocytes and lung macrophages. This would better define the relationship of TLR7, myelopoiesis, and respiratory viral infection.</p></disp-quote><p>We appreciate the point raised by the reviewer. In reply to the point # 2 of reviewer #1 we have amended the text to reflect more accurately the limitations of our experiments as they were just proof-of-concept. Further immune-phenotyping of lung monocytes and macrophages to assess their role in limiting the lung viral replication is beyond the scope of this manuscript. The monocytes that infiltrate the lungs may undergo a tissue adaptation and behave differently from the BM monocytes. Further studies will be required to define the specific adaptation of R848-treated monocytes following their migration in the lungs or other organs.</p><disp-quote content-type="editor-comment"><p>3. The images in Figure 6C are poor quality and hard to visualize. It is also not clear if they are intraparenchymal or intravascular.</p></disp-quote><p>We apologise for the reduced imagine quality of the PDF file. The original source image is of higher quality and has been uploaded in the <italic>eLife</italic> submission system. With regards to the macrophages being intravascular/intraparenchymal, this was addressed in figure 5D with the use of CD43 staining, where CD43<sup>high</sup> cells are intravascular monocytes as described by Kuriakose et al., 2019. We have shown that CD43<sup>high</sup> cells accumulate in the vasculature of the glomeruli, while CD68<sup>high</sup> CD43<sup>low</sup> remain in the kidney medulla.</p></body></sub-article></article>